SAPHO Syndrome

📘

Definitions

1

Kahn and Benhamou diagnostic criteria for SAPHO syndrome

The two criteria sets in common use. Benhamou's were published in 1988, Kahn's in 1994 and modified by the same author in 2003. All of them are built the same way - an osteoarticular manifestation paired with a form of SAPHO-typical skin disease, present or past - which is why an entry-level diagnosis can be made without any laboratory or histological finding. The consequential clause is in Kahn's set: chronic recurrent multifocal osteomyelitis in a child is by itself sufficient to diagnose SAPHO. That is what makes the boundary between this entry and Chronic Recurrent Multifocal Osteomyelitis a matter of convention rather than of biology, and it is the definitional basis of the nosology knowledge gap curated below. None of these criteria sets has been validated, and the contrast with the paediatric disease is instructive: CNO received jointly developed and externally validated EULAR/ACR classification criteria in 2025, while SAPHO has none.

PHENOTYPE_ALGORITHM DIAGNOSIS

Inclusion criteria

Osteoarticular manifestation with SAPHO-typical skin disease An osteoarticular manifestation - osteitis, hyperostosis or synovitis - paired with a form of SAPHO-typical skin disease, present or past. This pairing is the shared structure of every proposed criteria set.
Chronic recurrent multifocal osteomyelitis in a child Under Kahn's criteria this is by itself sufficient to diagnose SAPHO, with no skin disease required.
Inflammatory bowel disease association Incorporated into the modified 2003 Kahn criteria, which is what makes the IBD association structural to the diagnosis rather than incidental.

Exclusion criteria

Infectious osteomyelitis or spondylodiscitis Must be excluded; a monostotic lesion generally requires bone biopsy to do so.
Bone malignancy Osteosarcoma, Ewing sarcoma, bone metastasis, bone lymphoma and histiocytosis are all listed among the differentials to exclude.
Langerhans cell histiocytosis Named explicitly among the differentials to be excluded before diagnosis.

Show evidence (4 references)

PMID:38151265 SUPPORT Human Clinical

"Several sets of diagnostic or classification criteria have been proposed, of which the ones developed by, Kahn et al (1994 modified in 2003) and Benhamou et al are most commonly used across the literature"

Identifies the two criteria sets in common use and their revision history.

PMID:40004896 SUPPORT Human Clinical

"They are all based on the association between a bone and/or joint manifestation with a form of SAPHO"

Gives the shared structure of every proposed criteria set.

PMID:40004896 SUPPORT Human Clinical

"according to Kahn’s SAPHO diagnostic criteria, the presence of CRMO in children is sufficient for diagnosing SAPHO"

The clause that makes the SAPHO/CNO boundary definitional rather than biological, and the evidence behind the nosology knowledge gap.

+ 1 more reference

◈

Mechanistic Hypotheses

2

Canonical Autoinflammatory Cytokine Model

canonical_autoinflammatory_cytokine_model CANONICAL

Evidence balance 2 support

SAPHO arises from dysregulated innate immunity in a genetically predisposed host: neutrophil hyperactivity and excess IL-1 drive a self-amplifying TNF-alpha / IL-1beta / IL-6 / IL-8 / IL-23-IL-17 network that produces sterile osteitis, disordered bone remodelling and neutrophilic skin disease. The model is supported by the cytokine profile and by the therapeutic response to IL-1 and TNF blockade; its weakest point is that the predisposition itself has no identified genetic basis, so the model explains the amplification without explaining the initiation.

Show evidence (2 references)

PMID:37889264 SUPPORT Human Clinical

"Current evidence suggests that SAPHO results from a complex interplay between immune dysregulation, genetic susceptibility, and environmental factors."

States the three-factor model this hypothesis group formalises.

PMID:23153960 SUPPORT Human Clinical

"This suggests that the pathogenesis of SAPHO syndrome is multifactorial, but this aspect remains poorly explored, although bacteria and immunological dysfunction are hypothesized to play a role."

Supports the multifactorial framing while recording that it remains poorly explored, which is why the group is curated as canonical rather than established.

Emerging Cutibacterium acnes Trigger Model

emerging_cutibacterium_acnes_trigger_model EMERGING

Evidence balance 2 support

Low-grade intracellular persistence of Cutibacterium acnes in bone cells, rather than overt infection, supplies the recurrent NLRP3 inflammasome activation and IL-1beta release that drive the syndrome. This would make SAPHO a reactive osteitis in a susceptible host and would explain why the organism is culturable from lesions while antibiotics produce only transient benefit. It remains unproven: no controlled study establishes causation, and recovery of a commensal skin organism from a biopsy is equally consistent with contamination.

Pathograph links

Cutibacterium acnes Intraosseous Persistence -> Pro-Inflammatory Cytokine Amplification DIRECT Proposed route by which persistent intracellular C. acnes would drive the IL-1beta production that sustains the syndrome. Curated as belonging to the emerging hypothesis group, not as an established edge.

Show evidence (2 references)

PMID:28499891 SUPPORT Other

"As several auto-inflammatory bone disorders sharing overproduction of IL-1β can mimic SAPHO, this syndrome could partly depend on genetically encoded overproduction of IL-1β."

Gives the proposal's own framing - a partial, IL-1beta-centred contribution rather than a claim that the organism causes the disease.

PMID:39286247 SUPPORT Human Clinical

"Notably, infection with Propionibacterium acnes is believed to potentially trigger inflammatory responses by activating the immune system"

A contemporary review carries the proposal forward, but with hedged language ("believed to potentially"), which is the level of confidence curated here.

?

Discussions and Knowledge Gaps

3

Is Cutibacterium acnes recovered from SAPHO bone lesions a causal trigger of the osteitis, or a commensal contaminant of the biopsy?

KNOWLEDGE GAP gap_sapho_cutibacterium_acnes_trigger_or_contaminant

Attached to

pathophysiology#Cutibacterium acnes Intraosseous Persistence mechanistic_hypotheses#emerging_cutibacterium_acnes_trigger_model

Every element of the argument is currently compatible with both answers. C. acnes is a potent NLRP3 inflammasome activator and would supply the IL-1beta the rest of the mechanism requires, which is the case for causation. Against it: overt infection is absent in many patients, antibiotics produce only transient and incomplete benefit, and C. acnes is the commonest contaminant of any biopsy taken through skin - so recovery from a lesion is weak evidence either way. The question matters beyond taxonomy, because the two answers imply different diseases. If the organism is causal, SAPHO is a reactive osteitis in a susceptible host and antimicrobial strategy is undertreated; if it is a contaminant, the antibiotic exposure many patients receive is pure harm, which the clinical literature already flags as a consequence of delayed diagnosis.

Proposed experiments

Quantify C. acnes in SAPHO bone lesions against contamination-matched controls

exp_sapho_acnes_quantitative_culture_versus_controls

Compare organism burden in SAPHO lesional bone against two control sets that the existing literature lacks: unaffected bone from the same patients, and bone from non-SAPHO patients biopsied through skin by the same route. Contamination predicts similar low-level recovery across all three; a causal role predicts enrichment in lesional bone specifically. Pair this with intracellular localisation in bone cells, since the hypothesis is persistence rather than infection and a purely extracellular or surface-associated organism would not support it.

Would support

pathophysiology#Cutibacterium acnes Intraosseous Persistence

Would refute

pathophysiology#Cutibacterium acnes Intraosseous Persistence

Supporting outcome

Organism burden is significantly enriched in lesional bone relative to both control sets, with demonstrable intracellular localisation in bone-resident cells.

Refuting outcome

Recovery rates are indistinguishable across lesional bone, unaffected bone and non-SAPHO skin-route biopsies, consistent with contamination during sampling.

Are SAPHO syndrome and paediatric chronic nonbacterial osteomyelitis two diseases, or one disease observed at two ages?

KNOWLEDGE GAP gap_sapho_cno_nosology_one_disease_or_two

Attached to

disease#SAPHO Syndrome differential_diagnoses#Chronic nonbacterial osteomyelitis of childhood

The debate is live in the current literature rather than settled by convention. Kahn's criteria already treat CRMO in a child as sufficient to diagnose SAPHO; CNO can carry the same skin manifestations and the same IBD association; and adult CNO without skin disease is described. What separates them in practice is age at onset and the prominence of anterior chest wall hyperostosis, neither of which is obviously a difference in mechanism. dismech currently holds two entries, so the answer is not merely nosological here - it determines whether this entry and Chronic Recurrent Multifocal Osteomyelitis should eventually be one entry with age-stratified subtypes.

Proposed experiments

Jointly stratify SAPHO and CNO cohorts on innate signalling and treatment response

exp_sapho_cno_joint_molecular_stratification

Profile monocyte and neutrophil innate signalling, cytokine output and treatment response across an age-spanning cohort recruited under both diagnoses, and test whether the resulting clusters track diagnosis or track age. If clusters cut across both labels, the two are one disease and the diagnostic boundary is an artefact of which specialty sees the patient. If they separate cleanly by diagnosis independently of age, the entities are distinct and the shared features are convergent.

Would support

disease#SAPHO Syndrome

Would refute

disease#SAPHO Syndrome

Supporting outcome

Molecular and treatment-response clusters separate SAPHO from CNO independently of age at onset, supporting two distinct entities.

Refuting outcome

Clusters cut across the two diagnostic labels and track age or skin phenotype instead, indicating a single disease with age-dependent expression.

Why do the bone and skin compartments of SAPHO depend on different cytokines, and can that dissociation be used to choose therapy?

KNOWLEDGE GAP gap_sapho_compartment_specific_cytokine_dependency

Attached to

pathophysiology#Pro-Inflammatory Cytokine Amplification

The treatment data contain a clean, reproducible asymmetry that no current mechanistic account explains. IL-1 blockade produces musculoskeletal responses and is reported ineffective in skin; IL-17/IL-23 blockade does the reverse, improving skin while leaving rheumatic symptoms largely unchanged; anti-TNF works in bone and joint but can paradoxically provoke skin lesions. If SAPHO were a single cytokine-driven process, a given blockade should move both arms together. That it does not suggests the syndrome is two partially independent inflammatory programmes sharing an upstream innate defect - which would also explain why skin disease can be absent entirely, and why combination or compartment-directed therapy is not currently rational to prescribe because nobody has tested it. Two results cut against a clean dissociation and are curated rather than set aside. An open-label study reported pamidronate - a bone-directed agent - preventing recurrence of pustulosis in 9 of 10 refractory patients, though concomitant NSAIDs were permitted and others did not reproduce it. And the two tofacitinib pilot studies disagree with each other on bone, one reporting a response in 9 of 12 patients and the other reporting none. A JAK inhibitor acting on several hub cytokines at once is the natural test of whether the compartments are separable, and the existing data are too small and too discordant to answer it.

Proposed experiments

Paired lesional bone and skin cytokine profiling before and after single-agent blockade

exp_sapho_paired_bone_skin_cytokine_profiling

Sample lesional bone and lesional skin from the same patients before and after a defined course of single-agent IL-1, TNF or IL-17 blockade, and measure compartment-resolved cytokine and cellular profiles alongside compartment-specific clinical response. The discriminating result is whether the non-responding compartment shows an unchanged local cytokine profile - true independence - or a changed profile without clinical response, which would instead implicate established structural damage rather than ongoing cytokine drive.

Would support

pathophysiology#Pro-Inflammatory Cytokine Amplification

Would refute

pathophysiology#Pro-Inflammatory Cytokine Amplification

Supporting outcome

Blockade suppresses its target cytokine in both compartments but only the responding compartment shows resolution, locating the dissociation downstream of the shared hub.

Refuting outcome

Each compartment shows an independent cytokine profile unaffected by blockade of the other's dominant mediator, indicating two separate programmes rather than one hub.

⚙

Pathophysiology

10

Innate Immune Dysregulation

The upstream lesion, and the least well characterised. What is reproducibly reported is a set of innate abnormalities - neutrophil hyperactivity, reduced natural killer cell numbers, high IL-1 - together with a therapeutic response to IL-1 blockade. That combination is why contemporary reviews classify SAPHO as autoinflammatory rather than autoimmune. No causal gene underlies it: this node describes a functional state, not a genotype.

neutrophil CL:0000775

interleukin-1 beta production GO:0032611 ↑ INCREASED

Downstream

Pro-Inflammatory Cytokine Amplification

Show evidence (3 references)

PMID:37889264 SUPPORT Human Clinical

"It's not clear if SAPHO syndrome is an autoimmune disease or an autoinflammatory disease, but current evidence suggests that it's more likely an autoinflammatory disease because of things like neutrophil hyperactivity, fewer natural killer (NK) cells, high levels of interleukin (IL)-1, and a..."

Names the four innate observations that ground this node, and the reasoning by which the disease is classified as autoinflammatory.

PMID:20032092 REFUTE Human Clinical

"We found no association between PSTPIP2, NOD2, and LPIN2 variants and the SAPHO syndrome."

Refutes a monogenic account of this node in humans. The three genes tested were the strongest available candidates - two from mouse models of SAPHO-like disease, one from a clinically similar monogenic syndrome - and none was associated.

PMID:38151265 SUPPORT Human Clinical

"Synovitis acne pustulosis hyperostosis osteitis (SAPHO) is a rare heterogeneous disease of unknown aetiopathology."

Records that the aetiopathology is unknown, which is the epistemic status this node is curated at.

Cutibacterium acnes Intraosseous Persistence

A candidate initiating step, curated as a hypothesis rather than as established mechanism. Cutibacterium (formerly Propionibacterium) acnes is recovered from a proportion of SAPHO bone biopsies, and it is a potent activator of the NLRP3 inflammasome, which would supply the IL-1beta the rest of the chain depends on. The case against it is equally concrete: overt infection is absent in many patients and antibiotics produce only transient, incomplete benefit. The proposal that survives both observations is low-grade intracellular persistence rather than infection.

Emerging Cutibacterium acnes Trigger Model

NLRP3 inflammasome complex assembly GO:0044546 ↑ INCREASED

Downstream

Pro-Inflammatory Cytokine Amplification Proposed route by which persistent intracellular C. acnes would drive the IL-1beta production that sustains the syndrome. Curated as belonging to the emerging hypothesis group, not as an established edge.

Show evidence (2 references)

PMID:28499891 SUPPORT Other

"P. acnes is indeed a powerful trigger of NLRP3-inflammasome activation and IL-1β, leading to osteitis and enhanced mesenchymal cells differentiation in osteoblasts."

States the proposed molecular route from the organism to inflammasome activation and osteitis. The source is a hypothesis paper, graded OTHER accordingly.

PMID:28499891 SUPPORT Other

"Overt infection by Propionibacterium acnes is lacking in many SAPHO syndromes, and antibiotics have only a transient and incomplete effect, either in SAPHO syndrome or acne."

The countervailing observation, from the same source. It is why the node is framed as persistence rather than infection, and why the edge is hypothesis-scoped.

Pro-Inflammatory Cytokine Amplification

The hub of the disease. TNF-alpha, IL-1beta, IL-6, IL-8, IL-18 and the IL-23/IL-17 axis converge on NF-kappaB and MAPK signalling, each amplifying the others. This is a self-sustaining loop rather than a linear cascade, which is the mechanistic reason single-cytokine blockade helps many patients without curing any, and the reason different agents work in the bone and the skin compartments.

T-helper 17 cell CL:0000899 macrophage CL:0000235

tumor necrosis factor production GO:0032640 ↑ INCREASED interleukin-17 production GO:0032620 ↑ INCREASED positive regulation of canonical NF-kappaB signal transduction GO:0043123 ↑ INCREASED

Downstream

Neutrophil Recruitment and Activation

Bone Remodeling Imbalance

Show evidence (2 references)

PMID:39286247 SUPPORT Human Clinical

"Furthermore, the signaling pathways involving IL-1 and TNF-α are central to the pathophysiology of SAPHO syndrome, supporting the use of biologic treatments such as TNF-α inhibitors and IL-1 receptor antagonists"

Establishes IL-1 and TNF-alpha signalling as central, and ties that centrality to the therapeutic response that corroborates it.

PMID:39286247 SUPPORT Human Clinical

"In the pathogenesis of SAPHO syndrome, interleukin-23 (IL-23) and interleukin-17 (IL-17) form a critical cytokine axis significantly influencing inflammation and bone lesions."

Adds the IL-23/IL-17 arm, which is the axis the skin manifestations track most closely.

Neutrophil Recruitment and Activation

IL-8 recruits neutrophils to bone and skin and promotes their adherence and transendothelial migration; once there they degranulate and release reactive oxygen species. Neutrophils from patients are themselves hyperactive, secreting IL-8 and TNF-alpha and so feeding the upstream loop. This node is the reason the cutaneous lesions are neutrophilic pseudoabscesses and the bone lesions are neutrophil-rich.

neutrophil CL:0000775

neutrophil chemotaxis GO:0030593 ↑ INCREASED interleukin-8 production GO:0032637 ↑ INCREASED

Downstream

Sterile Osteitis

Neutrophilic Skin Inflammation

Show evidence (3 references)

PMID:39286247 SUPPORT Human Clinical

"In SAPHO syndrome, IL-8 primarily recruits and activates neutrophils at inflammation sites."

Establishes the chemokine-driven recruitment step this node describes.

PMID:39286247 SUPPORT Human Clinical

"Once activated, neutrophils release enzymes and reactive oxygen species that contribute to inflammatory damage in SAPHO syndrome, evident in bone resorption and skin lesions"

Links neutrophil effector function to damage in both compartments, which is why this node branches to bone and to skin.

PMID:39286247 SUPPORT Human Clinical

"neutrophils in patients with SAPHO syndrome demonstrate excessive activation, releasing substantial quantities of pro-inflammatory cytokines like IL-8 and TNF-α"

Documents the feedback arm by which activated neutrophils re-supply the cytokine hub.

Bone Remodeling Imbalance

The node that makes SAPHO bone disease distinctive. IL-1beta, IL-17, IL-6 and TNF-alpha each stimulate osteoclastogenesis while inhibiting osteoblast differentiation and function, so both arms of remodelling are deranged at once. The clinical consequence is not a single direction of bone change: lytic and sclerotic lesions coexist, and the net proliferative outcome at the anterior chest wall is what the acronym records as hyperostosis.

osteoclast CL:0000092 osteoblast CL:0000062

osteoclast differentiation GO:0030316 ↑ INCREASED bone resorption GO:0045453 ↑ INCREASED

Downstream

Hyperostosis and Osteosclerosis

Show evidence (2 references)

PMID:39286247 SUPPORT Human Clinical

"Additionally, in bone cells, IL-1β stimulates osteoclastogenesis, leading to increased bone resorption. IL-1β also inhibits osteoblast differentiation and function, impairing bone formation and repair."

States the dual, opposite-direction action on the two bone cell types that defines this node as an imbalance rather than as resorption alone.

PMID:39286247 SUPPORT Human Clinical

"In bone cells, IL-17 directly stimulates osteoclastogenesis, leading to increased bone resorption."

Adds IL-17 as a second cytokine acting on the same remodelling axis.

Sterile Osteitis

Inflammatory bone lesions with no causative organism. As in chronic nonbacterial osteomyelitis, this node is established by exclusion - by failing to isolate a pathogen, and by lesions that do not behave like infection over time - which is why diagnosis of the whole syndrome rests on ruling differentials out rather than on any positive test.

Animal models

PSTPIP2-knockout mouse Mouse partially recapitulates Reproduces sterile multifocal osteitis with synovitis and hyperostosis, together with the neutrophil infiltration and IL-1beta elevation that the human cytokine model predicts.

Downstream

Hyperostosis and Osteosclerosis

Synovitis

Show evidence (2 references)

PMID:38151265 SUPPORT Human Clinical

"diagnosing SAPHO relies on the presence of clinical features (including sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion of differential diagnoses (such as infections, tumours, Langerhans cell histiocytosis)"

Establishes sterile bone inflammation as a defining clinical feature and records that it is reached by exclusion.

PMID:34967407 SUPPORT Human Clinical

"Musculoskeletal manifestations, including osteitis, synovitis, and hyperostosis, are the hallmarks of the SAPHO syndrome and affect a variety of regions of the body."

Names osteitis as a hallmark manifestation alongside the two nodes it feeds.

Hyperostosis and Osteosclerosis

The proliferative bone response, and the feature that separates SAPHO from purely lytic sterile osteitis. Histologically the lesion evolves from an acute inflammatory infiltrate to marrow fibrosis and sclerosis of the bone trabeculae; radiologically it produces bone proliferation and hypertrophy of adjacent soft tissue, with a marked predilection for the sternum and clavicle and extension to the cervical spine and sacroiliac joints.

ossification GO:0001503 ↑ INCREASED

Downstream

Chronic Relapsing Osteoarticular and Cutaneous Disease

Show evidence (2 references)

PMID:39286247 SUPPORT Human Clinical

"Pathologically, bone lesions in SAPHO syndrome may present as acute inflammatory responses, and as the condition progresses, bone marrow fibrosis and significant sclerosis of bone trabeculae may develop"

Gives the histological trajectory from acute inflammation to sclerosis that this node describes.

PMID:39286247 SUPPORT Human Clinical

"Commonly, these bone alterations manifest in the anterior chest wall, including the sternum and clavicle, and extend to the cervical vertebrae and sacroiliac joints."

Establishes the anatomical distribution that makes anterior chest wall involvement the diagnostic clue.

Synovitis

Joint inflammation adjacent to affected bone, the S of the acronym. It is grouped with osteitis and hyperostosis as a musculoskeletal hallmark rather than treated as a separate arthropathy, and adjacent bone proliferation can itself impair joint function.

Downstream

Chronic Relapsing Osteoarticular and Cutaneous Disease

Show evidence (1 reference)

PMID:34967407 SUPPORT Human Clinical

"Musculoskeletal manifestations, including osteitis, synovitis, and hyperostosis, are the hallmarks of the SAPHO syndrome and affect a variety of regions of the body."

Establishes synovitis as one of the three musculoskeletal hallmarks.

Neutrophilic Skin Inflammation

The cutaneous arm, and the half of the syndrome that is often what brings a patient to attention. Lesions are neutrophilic - dermatoses characterised by neutrophilic pseudoabscesses - and the dominant forms are palmoplantar pustulosis and severe acne. Which of the two predominates is population-dependent rather than intrinsic to the disease. Skin lesions may precede, accompany or follow the skeletal ones, and can be absent altogether.

keratinocyte CL:0000312

Downstream

Chronic Relapsing Osteoarticular and Cutaneous Disease

Show evidence (2 references)

PMID:23153960 SUPPORT Human Clinical

"The SAHPO acronym identifies a syndrome encompassing a variety of osteoarticular disorders that are frequently accompanied by dermatoses characterized by neutrophilic pseudoabscesses, but can also occur in isolation."

Establishes the neutrophilic character of the dermatoses, and records that the osteoarticular disease can occur without them.

PMID:39286247 SUPPORT Human Clinical

"The dermatological manifestations of SAPHO syndrome vary, with the most prevalent being severe acne and pustular eczema, especially palmoplantar pustulosis."

Names the two dominant cutaneous forms.

Chronic Relapsing Osteoarticular and Cutaneous Disease

The clinical endpoint. The course is chronic and relapsing rather than monophasic or steadily progressive, and both the skeletal and dermatological arms are frequently the most debilitating features. Systemic inflammation adds constitutional symptoms - fever, weight loss, fatigue - and management is multidisciplinary because no single specialty sees the whole syndrome.

Show evidence (2 references)

PMID:37889264 SUPPORT Human Clinical

"Other clinical findings include constitutional symptoms caused by systemic inflammation, such as fever, weight loss, and fatigue."

Documents the systemic component of the clinical endpoint.

PMID:39286247 SUPPORT Human Clinical

"The clinical course of SAPHO syndrome is often chronic and relapsing, significantly impacting patients"

Establishes the chronic relapsing course that names this node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

11

Digestive 1

Inflammatory Bowel Disease Inflammation of the large intestine HP:0002037

Show evidence (2 references)

PMID:40004896 SUPPORT Human Clinical

"An association with IBD—which are also associated to neutrophilic dermatoses and SpA—has been known since SAPHO’s description"

Establishes the IBD association as recognised since the syndrome was first described.

PMID:40004896 SUPPORT Human Clinical

"is also part of the modified 2003 Kahn’s criteria"

Places the IBD association inside the diagnostic criteria, which is why it is curated as a phenotype rather than left to notes.

Immune 5

Sterile Osteitis Osteomyelitis HP:0002754

Show evidence (1 reference)

PMID:38151265 SUPPORT Human Clinical

"diagnosing SAPHO relies on the presence of clinical features (including sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion of differential diagnoses (such as infections, tumours, Langerhans cell histiocytosis)"

Names sterile bone inflammation as a defining clinical feature.

Palmoplantar Pustulosis HP:0100847

Show evidence (2 references)

PMID:39286247 SUPPORT Human Clinical

"The dermatological manifestations of SAPHO syndrome vary, with the most prevalent being severe acne and pustular eczema, especially palmoplantar pustulosis."

Establishes palmoplantar pustulosis as a leading cutaneous manifestation.

PMID:34967407 SUPPORT Human Clinical

"Recent survey indicated that more than 80% of cases of SAPHO syndrome in Japan were PAO, originally proposed by Sonozaki et al. in 1981, whereas severe acne was the most commonly reported skin ailment amongst participants with SAPHO syndrome in Israel."

Quantifies the population dependence of which cutaneous form predominates, which is why no single frequency band is asserted for either.

Severe Acne HP:0001061

Severity: SEVERE

Show evidence (1 reference)

PMID:39286247 SUPPORT Human Clinical

"acne (severe acneiform eruptions, often resistant to conventional treatments)"

Gives the definitional description of the acne component of the acronym.

Psoriasiform Skin Disease Psoriasiform dermatitis HP:0003765

Show evidence (1 reference)

PMID:37889264 SUPPORT Human Clinical

"Common skin lesions include psoriasis and acne, with hidradenitis suppurativa and neutrophilic dermatoses being less commonly seen."

Names psoriasis among the common cutaneous manifestations.

Hidradenitis Suppurativa Acne inversa HP:0040154

Show evidence (1 reference)

PMID:37889264 SUPPORT Human Clinical

"Common skin lesions include psoriasis and acne, with hidradenitis suppurativa and neutrophilic dermatoses being less commonly seen."

Names hidradenitis suppurativa as a less common cutaneous manifestation.

Metabolism 1

Elevated Acute Phase Reactants Elevated erythrocyte sedimentation rate HP:0003565

Show evidence (1 reference)

PMID:37889264 SUPPORT Human Clinical

"However, during active disease, there may be an increase in positive acute phase markers, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement levels, mild leukocytosis, and thrombocytosis."

Documents the acute phase response, and in the same source the absence of any SAPHO-specific laboratory marker.

Musculoskeletal 3

Hyperostosis HP:0100774

Show evidence (1 reference)

PMID:34967407 SUPPORT Human Clinical

"Musculoskeletal manifestations, including osteitis, synovitis, and hyperostosis, are the hallmarks of the SAPHO syndrome and affect a variety of regions of the body."

Establishes hyperostosis as a hallmark manifestation.

Synovitis HP:0100769

Show evidence (1 reference)

PMID:34967407 SUPPORT Human Clinical

"Musculoskeletal manifestations, including osteitis, synovitis, and hyperostosis, are the hallmarks of the SAPHO syndrome and affect a variety of regions of the body."

Establishes synovitis as a hallmark manifestation.

Sacroiliac Arthritis HP:0012317

Show evidence (1 reference)

PMID:39286247 SUPPORT Human Clinical

"Commonly, these bone alterations manifest in the anterior chest wall, including the sternum and clavicle, and extend to the cervical vertebrae and sacroiliac joints."

Establishes sacroiliac joint involvement as part of the skeletal distribution.

Constitutional 1

Bone Pain HP:0002653

Temporal: CHRONIC

Show evidence (1 reference)

PMID:39286247 SUPPORT Human Clinical

"Skeletal symptoms typically include pain and swelling in the anterior chest wall and chronic pain, often associated with bone proliferation and inflammation near joints."

Documents chronic bone pain and its anterior chest wall distribution.

💊

Medical Actions

8

Nonsteroidal Anti-Inflammatory Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: nonsteroidal anti-inflammatory drug NCIT:C257

Platform: Small molecule

First-line, together with analgesics. As in chronic nonbacterial osteomyelitis, no agent is licensed for SAPHO and every treatment below is used off-label; there are no prospective randomised controlled trials in this disease at all, because there are no externally validated diagnostic criteria or outcome measures to run them against.

Mechanism Target:

INHIBITS Sterile Osteitis — Suppresses the inflammatory bone lesion symptomatically without addressing the upstream innate dysregulation.

Show evidence (1 reference)

PMID:23153960 SUPPORT Human Clinical

"They include nonsteroidal anti-inflammatory drugs and analgesics as first-line agents."

Establishes NSAIDs as the first-line agents this link describes.

Show evidence (1 reference)

PMID:38151265 SUPPORT Human Clinical

"Externally validated and internationally agreed diagnostic criteria or outcomes and, as a result, prospective randomised controlled trials in SAPHO are absent."

Establishes the evidence-base limitation that qualifies every treatment curated in this entry.

TNF-alpha Blockade

Action: Pharmacotherapy NCIT:C15986

Agent: infliximab NCIT:C1789 adalimumab NCIT:C65216

Platform: Monoclonal antibody

The biologic of first choice in conventional-treatment-refractory disease. In a systematic review of 66 biologic-treated cases, anti-TNF agents gave the highest response rate in bone and joint manifestations of any class. The caveat is compartment-specific and paradoxical: anti-TNF treatment can itself provoke skin lesions in some patients.

Mechanism Target:

INHIBITS Pro-Inflammatory Cytokine Amplification — Removes TNF-alpha from the self-amplifying cytokine hub, which is where its effect on both the bone and the skin arms originates.

Show evidence (1 reference)

PMID:29773231 SUPPORT Human Clinical

"Data support a positive effect of anti-TNF treatment in SAPHO with a response rate in bone and joint manifestations of 93.3%."

Quantifies the osteoarticular response rate that grounds this treatment link.

Show evidence (2 references)

PMID:29773231 SUPPORT Human Clinical

"In SAPHO patients not responding to conventional treatment, TNF blockers appear to be the first choice."

Establishes anti-TNF as first-line biologic therapy.

PMID:39286247 SUPPORT Human Clinical

"Furthermore, other research has revealed that anti-TNF-α treatments can provoke skin lesions in some patients, highlighting the influential role of TNF-α in these dermatological manifestations."

Records the paradoxical cutaneous reaction, which is why the osteoarticular and dermatological responses to this agent must be assessed separately.

IL-1 Blockade

Action: Pharmacotherapy NCIT:C15986

Agent: anakinra NCIT:C38717

Platform: Protein replacement

Effective in the musculoskeletal compartment and, on the available data, not in the skin. That dissociation is mechanistically informative rather than a limitation of the evidence: it argues that the bone and skin arms of the syndrome do not depend on the same cytokine to the same degree.

Mechanism Target:

INHIBITS Pro-Inflammatory Cytokine Amplification — Blocks IL-1 receptor signalling within the cytokine hub. The response supports IL-1 as a load-bearing component of the osteoarticular arm specifically.

Show evidence (1 reference)

PMID:29773231 SUPPORT Human Clinical

"Data related to IL-1 inhibition in SAPHO are encouraging with most patients exhibiting a significant response in musculoskeletal manifestations (6/7, 85.7%). However, IL-1 inhibition is not effective in skin manifestations."

Gives both halves of the dissociation - musculoskeletal response and cutaneous non-response - from a single systematic review.

IL-17 and IL-23 Blockade

Action: Pharmacotherapy NCIT:C15986

Agent: secukinumab NCIT:C152315 ustekinumab NCIT:C84237

Platform: Monoclonal antibody

The mirror image of IL-1 blockade: efficacy concentrated in the skin, with little consistent osteoarticular benefit. Two independent sources report the same asymmetry, and both note paradoxical psoriasis flares as a class effect.

Mechanism Target:

INHIBITS Neutrophilic Skin Inflammation — Interrupts the IL-23/IL-17 arm of the cytokine hub, which is the arm the cutaneous manifestations track most closely.

Show evidence (1 reference)

PMID:39286247 SUPPORT Human Clinical

"One particular study on patients with SAPHO syndrome showed that treatment with Secukinumab, an IL-17 inhibitor, significantly alleviated skin lesions and joint pain, indicating a crucial role of IL-17 in the associated skin manifestations."

Supports IL-17 blockade acting on the cutaneous node.

Show evidence (3 references)

PMID:29773231 SUPPORT Human Clinical

"Data related to IL-17 blockade indicate efficacy in skin disease with 4/7 patients responding (57.1%). Joint/bone manifestations improved in 3/8 patients (37.5%)."

Quantifies the skin-versus-bone asymmetry for IL-17 blockade.

PMID:28532819 SUPPORT Human Clinical

"Regarding the rheumatic symptoms, no major improvement was obvious under any of the six treatment courses."

An independent case series reporting no major rheumatic improvement across six courses, corroborating the compartment asymmetry.

PMID:28532819 SUPPORT Human Clinical

"No particular safety concerns were reported, except cases of paradoxical psoriasis flare in one under ustekinumab and the other case under secukinumab."

Documents paradoxical psoriasis flare with both agents in this class.

Bisphosphonate Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: pamidronate CHEBI:7903 zoledronic acid CHEBI:46557

Platform: Small molecule

A treatment chosen for the specific shape of this disease. SAPHO combines increased bone remodelling with inflammatory osteitis, and bisphosphonates act on both - an antiosteoclastic effect and an anti-inflammatory one - which is why they are used here rather than as generic bone-protective agents.

Mechanism Target:

MODULATES Bone Remodeling Imbalance — Acts directly on the remodelling node by suppressing osteoclast activity, while its anti-inflammatory action reaches the osteitis.

Show evidence (1 reference)

PMID:12184437 SUPPORT Human Clinical

"SAPHO syndrome is characterized by both increased bone remodeling and inflammatory osteitis, indicating that it may respond favorably to pamidronate's dual mechanism of action."

States the dual-mechanism rationale that grounds this treatment link.

INHIBITS Neutrophilic Skin Inflammation — A contested link, curated because it cuts against this entry's own compartment argument. One open-label study reported pamidronate preventing recurrence of pustulosis in 9 of 10 patients refractory to several systemic agents - a bone-directed drug acting on skin. Concomitant NSAIDs were permitted, and other studies did not reproduce the effect, so the link is asserted weakly rather than dropped.

Show evidence (3 references)

PMID:38151265 SUPPORT Human Clinical

"Somewhat unexpectedly, one open-label study also reported beneficial effects of pamidronate on skin lesions, preventing recurrence of pustulosis in 9/10 patients (90%)"

The positive cutaneous result, from a single uncontrolled open-label study.

PMID:38151265 REFUTE Human Clinical

"However, NSAID use was permitted as concomitant treatment, which may have had additional effects."

The confound that prevents attributing the cutaneous benefit to pamidronate, from the same systematic review.

PMID:38151265 REFUTE Human Clinical

"Others did not confirm effects on the skin."

Records the failure to reproduce, which is why this link is curated as contested.

Show evidence (2 references)

PMID:12184437 SUPPORT Human Clinical

"Four of the five patients had a response after 1 week."

The observed response, from an uncontrolled series of five refractory patients - the scale of evidence available for this indication.

PMID:39286247 SUPPORT Human Clinical

"Recent studies have underscored the effectiveness of bisphosphonates, such as zoledronic acid, in alleviating pain and reducing inflammatory lesions in patients with SAPHO syndrome."

Corroborates the class effect with a second-generation agent.

Corticosteroids and Conventional DMARDs

Action: Pharmacotherapy NCIT:C15986

Agent: prednisolone CHEBI:8378 methotrexate CHEBI:44185 sulfasalazine CHEBI:9334

Platform: Small molecule

Escalation between NSAIDs and biologics. The honest summary of this tier is that it helps some patients and not others, which is itself the evidence cited for the pathogenesis being multifactorial.

Show evidence (2 references)

PMID:38151265 SUPPORT Human Clinical

"sulfasalazine (SSZ) reduce proinflammatory cytokine expression."

Names sulfasalazine among the conventional DMARDs used here, with the cytokine mechanism that places it against this entry's pathograph hub.

PMID:23153960 SUPPORT Human Clinical

"Systemic corticosteroids, disease-modifying anti-rheumatic drugs, biologicals targeting tumor necrosis factor alpha and interleukin-1, and bisphosphonates have all been beneficial in some patients, but ineffective in others."

Documents the inconsistent response across every drug class, which is the observation this tier is curated against.

Antibiotic Therapy

Action: Antibiotic Therapy NCIT:C15620

Agent: doxycycline CHEBI:50845 azithromycin CHEBI:2955

Platform: Small molecule

Used on the reasoning that C. acnes drives the disease. It is curated because its partial failure is mechanistically informative: benefit is transient and incomplete, which is a substantial part of the argument against overt infection as the cause. A corollary in the clinical literature runs the other way - recognising SAPHO promptly prevents patients being given long-term antibiotics they do not need.

Mechanism Target:

INHIBITS Cutibacterium acnes Intraosseous Persistence — Targets the hypothesised persistent organism. The incompleteness of the response is the informative part, and is one reason the C. acnes model is curated as emerging rather than canonical.

Show evidence (1 reference)

PMID:28499891 SUPPORT Other

"Overt infection by Propionibacterium acnes is lacking in many SAPHO syndromes, and antibiotics have only a transient and incomplete effect, either in SAPHO syndrome or acne."

Records the transient, incomplete antibiotic effect this link is curated around.

Show evidence (1 reference)

PMID:23153960 SUPPORT Human Clinical

"The early recognition, diagnosis, and prompt treatment of SAPHO syndrome can prevent the unnecessary use of long-term antibiotics or invasive procedures"

Frames prolonged antibiotic exposure as a harm of delayed diagnosis rather than as standard therapy.

JAK Inhibition

Action: Pharmacotherapy NCIT:C15986

Agent: tofacitinib CHEBI:71200

Platform: Small molecule

The newest class in use, and the one that most complicates the compartment story. Two pilot studies of tofacitinib disagree about bone: one reported a bone response in 9 of 12 patients alongside skin improvement, the other found significant benefit for nail and palmoplantar lesions with no clear osteoarticular efficacy - reduced pain but no MRI improvement. Both are small, open-label and unrandomised. Curated because a class with published prospective data belongs in the entry, and because the disagreement bears directly on whether the bone and skin compartments are separable.

Mechanism Target:

INHIBITS Pro-Inflammatory Cytokine Amplification — Blocks JAK-dependent signalling downstream of several of the cytokines in the hub at once, rather than neutralising a single one - which is the mechanistic reason it is a candidate for the compartment asymmetry the single-cytokine agents show.

Show evidence (1 reference)

PMID:38151265 SUPPORT Human Clinical

"One study investigated effects of the JAK inhibitor tofacitinib on dermatological manifestations in 13 Asian female SAPHO patients (12 weeks of 5 mg tofacitinib, twice daily)."

Identifies the prospective open-label study behind this treatment entry.

Show evidence (3 references)

PMID:38151265 SUPPORT Human Clinical

"Results were positive with significant benefit for nail lesions, palmoplantar pustulosis and associated quality of life."

Reports the cutaneous benefit observed in that study.

PMID:38151265 NO_EVIDENCE Human Clinical

"While a reduction of systemic inflammatory parameters was observed (CRP and ESR), no information was provided on bone involvement."

Records that the study reported nothing on the osteoarticular compartment, so it cannot be read either way on bone.

PMID:40004896 SUPPORT Human Clinical

"Li et al. treated 12 patients; 9 had a bone response and 7/8 experienced an improvement in skin manifestations (6 PPP and 1 acne)."

The second pilot study, reporting a bone response - which is the datum that disagrees with the first and is why this class is curated as unresolved on bone.

🔬

Diagnosis

5

Diagnosis of Exclusion

There is no specific laboratory finding for SAPHO and no validated criteria set, so diagnosis rests on recognising a compatible clinical picture and excluding the alternatives. Infection and malignancy are the two that matter, and the monostotic lesion is the hard case - a single sclerotic or lytic lesion without skin disease is not distinguishable from osteomyelitis or a bone tumour on imaging alone.

diagnosis of exclusion

Show evidence (2 references)

PMID:38151265 SUPPORT Human Clinical

"diagnosing SAPHO relies on the presence of clinical features (including sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion of differential diagnoses (such as infections, tumours, Langerhans cell histiocytosis)"

States the exclusion-based structure of the diagnostic approach.

PMID:37889264 SUPPORT Human Clinical

"There is no specific laboratory finding for SAPHO syndrome."

Establishes the absence of a diagnostic biomarker, which is a property of the disease rather than a gap in this entry's sourcing.

Magnetic Resonance Imaging

Proposed as the gold standard modality, because it detects bone marrow oedema - the osteitis itself - as well as erosions and ankylosis. The case for it over plain films is quantitative and stark: at early stages conventional radiography shows only 16% of the lesions MRI sees, so a normal radiograph does not exclude active disease.

Magnetic Resonance Imaging NCIT:C16809

Show evidence (2 references)

PMID:40004896 SUPPORT Human Clinical

"Magnetic resonance imaging (MRI) has been suggested as a gold standard diagnostic modality for its ability to detect osteitis (bone marrow oedema) as well as structural lesions, like erosions and ankyloses"

Establishes MRI as the proposed reference modality and what it detects.

PMID:40004896 SUPPORT Human Clinical

"Fritz et al. found that, at early stages, conventional radiography only shows 16% of the lesions seen on MRI"

Quantifies the sensitivity gap that makes MRI rather than radiography the reference test.

Bone Scintigraphy

Whole-skeleton survey, which is what makes it useful in a multifocal disease: it assesses every involved site at once and helps rule out malignancy and infection. Its contribution to positive diagnosis is the bull's head sign - symmetrical uptake across the sternoclavicular region - which is characteristic of SAPHO but insensitive, so its absence carries little weight.

Bone Scan NCIT:C17646

Show evidence (2 references)

PMID:40004896 SUPPORT Human Clinical

"Bone scintigraphy has many advantages, as it can assess multiple involved sites, as well as rule out malignancy and infection."

States the whole-skeleton and exclusion roles of scintigraphy.

PMID:40004896 SUPPORT Human Clinical

"sign, seen with this technique, describes a symmetric uptake in the sternoclavicular region; it is characteristic but not highly sensitive"

Describes the bull's head sign and records that it is characteristic but not sensitive - which is why it is graded PARTIAL as a diagnostic test.

Bone Biopsy

Reserved for the case the imaging cannot settle. A monostotic lesion is the specific indication, because that is where the infectious and neoplastic hypotheses cannot be excluded on distribution.

Biopsy of Bone NCIT:C51927

Show evidence (1 reference)

PMID:40004896 SUPPORT Human Clinical

"the infectious and neoplastic hypothesis should be always ruled out, especially when confronting a monostotic lesion, by means of a bone biopsy."

Names the indication for biopsy and the two hypotheses it is used to exclude.

Multimodal Imaging Assessment

No single modality does the whole job. Radiographs and CT show structural change, scintigraphy surveys the skeleton, and MRI, whole-body MRI and PET-CT detect lesions before structural damage and report soft tissue involvement.

Positron Emission Tomography NCIT:C17007

Show evidence (2 references)

PMID:38151265 SUPPORT Human Clinical

"Alongside radiographic imaging (plain radiographs, CT), bone scintigraphy, MRI, whole-body MRI and positron emission tomography (PET) CT are considered key diagnostic tools."

Names the full set of modalities considered key to diagnosis.

PMID:38151265 SUPPORT Human Clinical

"MRI and PET CT enable early detection of bone lesions prior to structural damage, and provide information on soft tissue involvement."

Distinguishes what the cross-sectional modalities add over radiographs and CT.

📊

Prevalence

2

Caucasian populations

Unknown 10.0 per 100,000 1–9 per 10,000

Reported as "1 in 10,000". The two reviews carrying this figure trace it to the same source but label it differently - one calls it a frequency, the other an incidence - so measure_type is left UNKNOWN rather than guessed. Both state the true figure is unknown and likely higher because the disease is misdiagnosed or misclassified.

Show evidence (1 reference)

PMID:37889264 SUPPORT Human Clinical

"SAPHO syndrome is rare, with a reported frequency of 1 in 10,000 in the Caucasian population."

Source of the numeric estimate curated here.

Worldwide

Point Prevalence Rare

Estimated at below 1 in 10,000 in the explicit absence of reliable epidemiological data. Curated in the qualitative RARE band rather than a numeric Orphanet tier because the source gives only an upper bound.

Show evidence (1 reference)

PMID:38151265 SUPPORT Human Clinical

"In the absence of reliable epidemiological data, a prevalence of <1/10 000 has been estimated."

Source of the upper-bound estimate and of the caveat about data quality.

🌍

Epidemiology

2

Age at onset and sex distribution

Onset is typically in the third to fifth decade, which is the main axis separating SAPHO from paediatric CNO/CRMO in practice. A female predominance is reported, but it is not uniform: it is most evident in early-onset disease, and it inverts by cutaneous phenotype - severe acne is commoner in men, palmoplantar pustulosis and psoriasis in women. That is a second axis of population dependence alongside the geographic one, and it is the reason no single frequency band is asserted for either skin form.

Show evidence (3 references)

PMID:40004896 SUPPORT Human Clinical

"Disease onset is considered between the third and fifth decade of life"

Source of the age-at-onset window, which previously appeared only as an unevidenced differential bullet.

PMID:40004896 SUPPORT Human Clinical

"severe acne is more frequent in men, whereas palmoplantar pustulosis and psoriasis are more common in females"

Documents the sex split by cutaneous phenotype, which qualifies any single statement of female predominance.

PMID:38151265 SUPPORT Human Clinical

"a female predilection (approximately 2.2:1) has been suggested"

An independent estimate of the sex ratio from a systematic review.

Comorbidity burden

Comorbidity data are sparse and come largely from single groups, so these are reported rather than treated as established disease features. The pattern that does recur is cardiometabolic - hypertension is the commonest reported comorbidity and metabolic syndrome is more prevalent than in controls - alongside increased osteoporosis and a substantial fibromyalgia fraction, the latter mattering because it confounds the pain outcome that every SAPHO treatment is judged on.

Show evidence (2 references)

PMID:40004896 SUPPORT Human Clinical

"Przepiera-Będzak et al. reported hypertension (25%) as the most common comorbidity, followed by hypothyroidism and diabetes (9.6% each)"

Gives the reported comorbidity frequencies. Graded PARTIAL because the source itself states that few data are available.

PMID:40004896 SUPPORT Human Clinical

"Lastly, a recent Chinese study found an 18% prevalence of fibromyalgia, which was also associated to female sex and older age"

Documents the fibromyalgia fraction, which is directly relevant to interpreting pain-based treatment response in this disease.

🔀

Differential Diagnoses

6

Conditions with similar clinical presentations that must be differentiated from SAPHO Syndrome:

Bacterial osteomyelitis

Overlapping Features The differential the sterile osteitis is defined against, and a formal exclusion in every proposed criteria set. Imaging and histology can be indistinguishable, and the cost of error runs both ways - antibiotics and surgery for an inflammatory disease, or immunosuppression for an untreated infection.

Distinguishing Features

No causative organism accounts for the lesions in SAPHO
Antibiotics give only transient and incomplete benefit in SAPHO
Anterior chest wall hyperostosis and accompanying neutrophilic skin disease are not features of bacterial osteomyelitis

Show evidence (1 reference)

PMID:38151265 SUPPORT Human Clinical

"diagnosing SAPHO relies on the presence of clinical features (including sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion of differential diagnoses (such as infections, tumours, Langerhans cell histiocytosis)"

Establishes infection as a formal exclusion in the diagnostic approach.

Bone malignancy

Overlapping Features Primary bone tumours and metastatic disease can produce sclerotic or lytic lesions with pain in the same distribution. Formally excluded before a SAPHO diagnosis is made, and the reason biopsy is often performed.

Distinguishing Features

Formal exclusion in the clinical diagnostic approach
SAPHO lesions are typically multifocal with a relapsing rather than progressive course
Accompanying neutrophilic skin disease points away from malignancy

Show evidence (1 reference)

PMID:38151265 SUPPORT Human Clinical

"diagnosing SAPHO relies on the presence of clinical features (including sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion of differential diagnoses (such as infections, tumours, Langerhans cell histiocytosis)"

Names tumours as a formal exclusion.

Langerhans cell histiocytosis

Overlapping Features A specific named exclusion rather than a generic one. It produces multifocal bone lesions with skin involvement, which is precisely the SAPHO pattern, so it is excluded on histology rather than on distribution.

Distinguishing Features

Named explicitly among the differentials to be excluded
Distinguished by lesional histology rather than by lesion distribution

Show evidence (1 reference)

PMID:38151265 SUPPORT Human Clinical

"diagnosing SAPHO relies on the presence of clinical features (including sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion of differential diagnoses (such as infections, tumours, Langerhans cell histiocytosis)"

Names Langerhans cell histiocytosis as a specific exclusion.

Chronic nonbacterial osteomyelitis of childhood

Overlapping Features Not straightforwardly a differential. CNO/CRMO shares the sterile multifocal osteitis and can share the skin manifestations, and whether it is a distinct condition or the paediatric expression of the same disease is actively debated. Kahn's criteria treat the presence of CRMO in a child as sufficient for a SAPHO diagnosis, which makes the boundary a matter of convention rather than of biology. Curated as a differential because dismech holds a separate entry for it.

Distinguishing Features

CNO/CRMO presents in children and adolescents; SAPHO onset is typically the third to fifth decade
Anterior chest wall hyperostosis is more characteristic of adult SAPHO
Under Kahn's criteria, CRMO in a child is itself sufficient to diagnose SAPHO

Show evidence (1 reference)

PMID:40004896 SUPPORT Human Clinical

"However, there is an ongoing debate about whether SAPHO syndrome and CNO are distinct conditions or simply represent different manifestations of the same disease depending on the age at onset"

Records the unresolved nosology directly, which is why this is curated as a contested boundary rather than a clean differential.

Monogenic autoinflammatory bone diseases

Overlapping Features The mechanistically informative differential group, and the one that shows what SAPHO would look like if it had a single cause. PAPA, DIRA, DITRA and Majeed syndrome each produce sterile osteitis with neutrophilic skin disease from a defined gene, and each has a correspondingly clean cytokine dependency. SAPHO has neither - which is exactly the contrast that makes its heterogeneous treatment response the thing a mechanistic account has to explain.

Distinguishing Features

Each has an identified causal gene; SAPHO has none, and its three strongest candidates were excluded in a human cohort
Onset is typically neonatal or paediatric rather than the third to fifth decade
Cytokine dependency is defined and single-agent responsive, unlike SAPHO's heterogeneous response across every drug class

Show evidence (1 reference)

PMID:40004896 SUPPORT Human Clinical

"Monogenic autoinflammatory bone diseases: PAPA syndrome, DIRA syndrome, deficiency of interleukin-36 receptor antagonist (DITRA) syndrome, or Majeed syndrome."

Names the four monogenic differentials to be considered.

Spondyloarthritis

Overlapping Features Overlaps SAPHO on almost every clinical axis - peripheral arthritis, enthesitis, sacroiliac and spinal involvement, psoriasis, inflammatory bowel disease - which is why the two are periodically proposed as the same family. The discriminator is genetic and clean: SAPHO shows no increase in HLA-B27 frequency, unlike SpA. MRI adds a second: SAPHO has lower rates of sacroiliitis and erosion but more anterior chest wall involvement.

Distinguishing Features

SAPHO shows no increased HLA-B27 frequency, unlike spondyloarthritis
Anterior chest wall involvement is commoner in SAPHO; sacroiliitis and erosions less common
Hyperostosis and osteitis rather than a purely erosive or ankylosing pattern

Show evidence (2 references)

PMID:40004896 SUPPORT Human Clinical

"genetic reports on SAPHO syndrome did not show an increase in HLA-B27 frequency, unlike in SpA"

The genetic discriminator separating SAPHO from spondyloarthritis.

PMID:40004896 SUPPORT Human Clinical

"The former, in fact, had lower incidence of both sacroiliitis and erosions, as well as a higher incidence of anterior chest wall involvement."

The imaging discriminator, from a direct SAPHO-versus-SpA MRI comparison.

🐁

Animal Models

1

PSTPIP2-knockout mouse

Germline Pstpip2 knockout mice develop paw swelling, synovitis, hyperostosis and osteitis with multifocal osteomyelitis, marked neutrophil and macrophage infiltration of bone, joint and skin, and elevated neutrophil-attracting chemokines and IL-1beta - a phenocopy of the human syndrome arising from a single defined gene.

Species

Mouse

Genotype

Pstpip2 knockout (Pstpip2-/-)

Publication

PMID:25602062

Pathograph links

Sterile Osteitis partially recapitulates fidelity: moderate Reproduces sterile multifocal osteitis with synovitis and hyperostosis, together with the neutrophil infiltration and IL-1beta elevation that the human cytokine model predicts.

Limitations: The gene is the problem. A candidate-gene study of 38 human SAPHO patients found no association with PSTPIP2, so the mouse establishes that loss of one innate regulator can produce a SAPHO-like phenotype, not that this is the human mechanism. The bone phenotype also diverges in direction: the mouse develops profound osteolytic lesions with decreased bone volume density, whereas proliferative hyperostosis and osteosclerosis are the human radiological signature.

Readouts

Neutrophil and macrophage infiltration of bone, joint and skin

Direction: INCREASED

Interpretation: Cellular correlate of the sterile osteitis node, in the same three compartments the human syndrome involves.

Show evidence (1 reference)

PMID:25602062 SUPPORT Model Organism

"Multifocal osteomyelitis was found in inflamed paws, with increased macrophage and marked neutrophil infiltrations in the bone, joint and skin."

Reports the histological measurement behind this readout.

Tissue IL-1beta and neutrophil-attracting chemokines

Direction: INCREASED

Interpretation: Confirms in a model system the two mediators the human cytokine hub and the neutrophil recruitment node depend on.

Show evidence (1 reference)

PMID:25602062 SUPPORT Model Organism

"Neutrophil-attracting chemokines and IL-1β were markedly elevated in inflamed tissues."

Reports the cytokine and chemokine measurement behind this readout.

Show evidence (1 reference)

PMID:25602062 SUPPORT Model Organism

"All Pstpip2(-/-) mice developed paw swelling, synovitis, hyperostosis and osteitis, resembling SAPHO syndrome, an inflammatory disorder of the bone, skin and joints."

Supports treating this model as informative for the sterile osteitis node, with full penetrance of the SAPHO-like phenotype.

Show evidence (1 reference)

PMID:20032092 SUPPORT Human Clinical

"Genetic studies of HLA genes have shown no role for these class II antigens, whereas studies of 2 mouse models (cmo and Lupo) point to a role of the PSTPIP2 gene."

Records why PSTPIP2 was the candidate worth testing in humans - two independent mouse models - which is the same reason this model is curated here.

{ }

Source YAML

click to show

name: SAPHO Syndrome
creation_date: "2026-08-27T00:00:00Z"
category: Complex
synonyms:
- Synovitis, acne, pustulosis, hyperostosis, osteitis syndrome
- Synovitis-acne-pustulosis-hyperostosis-osteitis syndrome
- Acquired hyperostosis syndrome
- Pustulo-psoriatic hyperostotic spondyloarthritis
- Pustulotic arthro-osteitis
- PPHS
description: >-
  SAPHO syndrome is an autoinflammatory disorder that couples sterile inflammatory bone
  disease to neutrophilic skin disease. The acronym names its five components -
  synovitis, acne, pustulosis, hyperostosis and osteitis - and the syndrome is defined by
  their co-occurrence rather than by any one of them.

  The central negative feature is the same one that defines its paediatric counterpart:
  the osteitis is sterile. Lesions can look infectious on imaging and on histology, but
  no organism accounts for them and antibiotics do not durably treat them. What
  distinguishes SAPHO from most sterile osteitis is what the bone does next - it
  proliferates. Hyperostosis and osteosclerosis of the anterior chest wall, with marrow
  fibrosis and thickened trabeculae, are the radiological signature, so the bone lesion
  is not simply lytic inflammation but a remodelling failure in which formation and
  resorption are both deranged.

  Mechanistically it is an innate immune disorder. Neutrophil hyperactivity, elevated
  IL-1 and a therapeutic response to IL-1 blockade are the reasons current reviews
  classify it as autoinflammatory rather than autoimmune, and TNF-alpha, IL-1beta, IL-6,
  IL-8 and the IL-23/IL-17 axis are all implicated in both the bone and the skin
  compartments. No causal gene is established. Two mouse models point to PSTPIP2, but a
  human candidate-gene study of 38 patients found no association with PSTPIP2, NOD2 or
  LPIN2, and this entry curates that discordance rather than smoothing it over.

  Two things about this disease are genuinely unsettled and are curated as such: whether
  Cutibacterium (formerly Propionibacterium) acnes recovered from bone lesions is a
  trigger or a contaminant, and whether SAPHO and paediatric chronic nonbacterial
  osteomyelitis are two diseases or one disease seen at two ages.
disease_term:
  preferred_term: SAPHO syndrome
  term:
    id: MONDO:0019266
    label: SAPHO syndrome
parents:
- Autoinflammatory Syndrome

pathophysiology:
- name: Innate Immune Dysregulation
  biological_scale: CELLULAR
  description: >-
    The upstream lesion, and the least well characterised. What is reproducibly reported
    is a set of innate abnormalities - neutrophil hyperactivity, reduced natural killer
    cell numbers, high IL-1 - together with a therapeutic response to IL-1 blockade. That
    combination is why contemporary reviews classify SAPHO as autoinflammatory rather
    than autoimmune. No causal gene underlies it: this node describes a functional state,
    not a genotype.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: interleukin-1 beta production
    term:
      id: GO:0032611
      label: interleukin-1 beta production
    modifier: INCREASED
  downstream:
  - target: Pro-Inflammatory Cytokine Amplification
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:37889264
    reference_title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "It's not clear if SAPHO syndrome is an autoimmune disease or an
      autoinflammatory disease, but current evidence suggests that it's more likely an
      autoinflammatory disease because of things like neutrophil hyperactivity, fewer
      natural killer (NK) cells, high levels of interleukin (IL)-1, and a good response
      to treatments that block IL-1."
    explanation: >-
      Names the four innate observations that ground this node, and the reasoning by
      which the disease is classified as autoinflammatory.
  - reference: PMID:20032092
    reference_title: "Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "We found no association between PSTPIP2, NOD2, and LPIN2 variants and the
      SAPHO syndrome."
    explanation: >-
      Refutes a monogenic account of this node in humans. The three genes tested were the
      strongest available candidates - two from mouse models of SAPHO-like disease, one
      from a clinically similar monogenic syndrome - and none was associated.
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Synovitis acne pustulosis hyperostosis osteitis (SAPHO) is a rare
      heterogeneous disease of unknown aetiopathology."
    explanation: >-
      Records that the aetiopathology is unknown, which is the epistemic status this node
      is curated at.

- name: Cutibacterium acnes Intraosseous Persistence
  biological_scale: CELLULAR
  description: >-
    A candidate initiating step, curated as a hypothesis rather than as established
    mechanism. Cutibacterium (formerly Propionibacterium) acnes is recovered from a
    proportion of SAPHO bone biopsies, and it is a potent activator of the NLRP3
    inflammasome, which would supply the IL-1beta the rest of the chain depends on. The
    case against it is equally concrete: overt infection is absent in many patients and
    antibiotics produce only transient, incomplete benefit. The proposal that survives
    both observations is low-grade intracellular persistence rather than infection.
  biological_processes:
  - preferred_term: NLRP3 inflammasome complex assembly
    term:
      id: GO:0044546
      label: NLRP3 inflammasome complex assembly
    modifier: INCREASED
  downstream:
  - target: Pro-Inflammatory Cytokine Amplification
    causal_link_type: DIRECT
    hypothesis_groups:
    - emerging_cutibacterium_acnes_trigger_model
    description: >-
      Proposed route by which persistent intracellular C. acnes would drive the
      IL-1beta production that sustains the syndrome. Curated as belonging to the
      emerging hypothesis group, not as an established edge.
  evidence:
  - reference: PMID:28499891
    reference_title: "SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "P. acnes is indeed a powerful trigger of NLRP3-inflammasome activation and
      IL-1β, leading to osteitis and enhanced mesenchymal cells differentiation in
      osteoblasts."
    explanation: >-
      States the proposed molecular route from the organism to inflammasome activation
      and osteitis. The source is a hypothesis paper, graded OTHER accordingly.
  - reference: PMID:28499891
    reference_title: "SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Overt infection by Propionibacterium acnes is lacking in many SAPHO
      syndromes, and antibiotics have only a transient and incomplete effect, either in
      SAPHO syndrome or acne."
    explanation: >-
      The countervailing observation, from the same source. It is why the node is framed
      as persistence rather than infection, and why the edge is hypothesis-scoped.

- name: Pro-Inflammatory Cytokine Amplification
  biological_scale: MOLECULAR
  description: >-
    The hub of the disease. TNF-alpha, IL-1beta, IL-6, IL-8, IL-18 and the IL-23/IL-17
    axis converge on NF-kappaB and MAPK signalling, each amplifying the others. This is
    a self-sustaining loop rather than a linear cascade, which is the mechanistic reason
    single-cytokine blockade helps many patients without curing any, and the reason
    different agents work in the bone and the skin compartments.
  biological_processes:
  - preferred_term: tumor necrosis factor production
    term:
      id: GO:0032640
      label: tumor necrosis factor production
    modifier: INCREASED
  - preferred_term: interleukin-17 production
    term:
      id: GO:0032620
      label: interleukin-17 production
    modifier: INCREASED
  - preferred_term: positive regulation of canonical NF-kappaB signal transduction
    term:
      id: GO:0043123
      label: positive regulation of canonical NF-kappaB signal transduction
    modifier: INCREASED
  cell_types:
  - preferred_term: T-helper 17 cell
    term:
      id: CL:0000899
      label: T-helper 17 cell
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  downstream:
  - target: Neutrophil Recruitment and Activation
    causal_link_type: DIRECT
  - target: Bone Remodeling Imbalance
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, the signaling pathways involving IL-1 and TNF-α are central to
      the pathophysiology of SAPHO syndrome, supporting the use of biologic treatments
      such as TNF-α inhibitors and IL-1 receptor antagonists"
    explanation: >-
      Establishes IL-1 and TNF-alpha signalling as central, and ties that centrality to
      the therapeutic response that corroborates it.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the pathogenesis of SAPHO syndrome, interleukin-23 (IL-23) and
      interleukin-17 (IL-17) form a critical cytokine axis significantly influencing
      inflammation and bone lesions."
    explanation: Adds the IL-23/IL-17 arm, which is the axis the skin manifestations track most closely.

- name: Neutrophil Recruitment and Activation
  biological_scale: CELLULAR
  description: >-
    IL-8 recruits neutrophils to bone and skin and promotes their adherence and
    transendothelial migration; once there they degranulate and release reactive oxygen
    species. Neutrophils from patients are themselves hyperactive, secreting IL-8 and
    TNF-alpha and so feeding the upstream loop. This node is the reason the cutaneous
    lesions are neutrophilic pseudoabscesses and the bone lesions are neutrophil-rich.
  cell_types:
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  biological_processes:
  - preferred_term: neutrophil chemotaxis
    term:
      id: GO:0030593
      label: neutrophil chemotaxis
    modifier: INCREASED
  - preferred_term: interleukin-8 production
    term:
      id: GO:0032637
      label: interleukin-8 production
    modifier: INCREASED
  downstream:
  - target: Sterile Osteitis
    causal_link_type: DIRECT
  - target: Neutrophilic Skin Inflammation
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In SAPHO syndrome, IL-8 primarily recruits and activates neutrophils at
      inflammation sites."
    explanation: Establishes the chemokine-driven recruitment step this node describes.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once activated, neutrophils release enzymes and reactive oxygen species
      that contribute to inflammatory damage in SAPHO syndrome, evident in bone
      resorption and skin lesions"
    explanation: >-
      Links neutrophil effector function to damage in both compartments, which is why
      this node branches to bone and to skin.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "neutrophils in patients with SAPHO syndrome demonstrate excessive
      activation, releasing substantial quantities of pro-inflammatory cytokines like
      IL-8 and TNF-α"
    explanation: Documents the feedback arm by which activated neutrophils re-supply the cytokine hub.

- name: Bone Remodeling Imbalance
  biological_scale: CELLULAR
  description: >-
    The node that makes SAPHO bone disease distinctive. IL-1beta, IL-17, IL-6 and
    TNF-alpha each stimulate osteoclastogenesis while inhibiting osteoblast
    differentiation and function, so both arms of remodelling are deranged at once. The
    clinical consequence is not a single direction of bone change: lytic and sclerotic
    lesions coexist, and the net proliferative outcome at the anterior chest wall is what
    the acronym records as hyperostosis.
  cell_types:
  - preferred_term: osteoclast
    term:
      id: CL:0000092
      label: osteoclast
  - preferred_term: osteoblast
    term:
      id: CL:0000062
      label: osteoblast
  biological_processes:
  - preferred_term: osteoclast differentiation
    term:
      id: GO:0030316
      label: osteoclast differentiation
    modifier: INCREASED
  - preferred_term: bone resorption
    term:
      id: GO:0045453
      label: bone resorption
    modifier: INCREASED
  downstream:
  - target: Hyperostosis and Osteosclerosis
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, in bone cells, IL-1β stimulates osteoclastogenesis, leading
      to increased bone resorption. IL-1β also inhibits osteoblast differentiation and
      function, impairing bone formation and repair."
    explanation: >-
      States the dual, opposite-direction action on the two bone cell types that defines
      this node as an imbalance rather than as resorption alone.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In bone cells, IL-17 directly stimulates osteoclastogenesis, leading to
      increased bone resorption."
    explanation: Adds IL-17 as a second cytokine acting on the same remodelling axis.

- name: Sterile Osteitis
  biological_scale: TISSUE
  description: >-
    Inflammatory bone lesions with no causative organism. As in chronic nonbacterial
    osteomyelitis, this node is established by exclusion - by failing to isolate a
    pathogen, and by lesions that do not behave like infection over time - which is why
    diagnosis of the whole syndrome rests on ruling differentials out rather than on any
    positive test.
  downstream:
  - target: Hyperostosis and Osteosclerosis
    causal_link_type: DIRECT
  - target: Synovitis
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diagnosing SAPHO relies on the presence of clinical features (including
      sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion
      of differential diagnoses (such as infections, tumours, Langerhans cell
      histiocytosis)"
    explanation: >-
      Establishes sterile bone inflammation as a defining clinical feature and records
      that it is reached by exclusion.
  - reference: PMID:34967407
    reference_title: SAPHO syndrome and pustulotic arthro-osteitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Musculoskeletal manifestations, including osteitis, synovitis, and
      hyperostosis, are the hallmarks of the SAPHO syndrome and affect a variety of
      regions of the body."
    explanation: Names osteitis as a hallmark manifestation alongside the two nodes it feeds.

- name: Hyperostosis and Osteosclerosis
  biological_scale: TISSUE
  description: >-
    The proliferative bone response, and the feature that separates SAPHO from purely
    lytic sterile osteitis. Histologically the lesion evolves from an acute inflammatory
    infiltrate to marrow fibrosis and sclerosis of the bone trabeculae; radiologically it
    produces bone proliferation and hypertrophy of adjacent soft tissue, with a marked
    predilection for the sternum and clavicle and extension to the cervical spine and
    sacroiliac joints.
  biological_processes:
  - preferred_term: ossification
    term:
      id: GO:0001503
      label: ossification
    modifier: INCREASED
  downstream:
  - target: Chronic Relapsing Osteoarticular and Cutaneous Disease
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathologically, bone lesions in SAPHO syndrome may present as acute
      inflammatory responses, and as the condition progresses, bone marrow fibrosis and
      significant sclerosis of bone trabeculae may develop"
    explanation: Gives the histological trajectory from acute inflammation to sclerosis that this node describes.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Commonly, these bone alterations manifest in the anterior chest wall,
      including the sternum and clavicle, and extend to the cervical vertebrae and
      sacroiliac joints."
    explanation: Establishes the anatomical distribution that makes anterior chest wall involvement the diagnostic clue.

- name: Synovitis
  biological_scale: TISSUE
  description: >-
    Joint inflammation adjacent to affected bone, the S of the acronym. It is grouped
    with osteitis and hyperostosis as a musculoskeletal hallmark rather than treated as a
    separate arthropathy, and adjacent bone proliferation can itself impair joint
    function.
  downstream:
  - target: Chronic Relapsing Osteoarticular and Cutaneous Disease
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34967407
    reference_title: SAPHO syndrome and pustulotic arthro-osteitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Musculoskeletal manifestations, including osteitis, synovitis, and
      hyperostosis, are the hallmarks of the SAPHO syndrome and affect a variety of
      regions of the body."
    explanation: Establishes synovitis as one of the three musculoskeletal hallmarks.

- name: Neutrophilic Skin Inflammation
  biological_scale: TISSUE
  description: >-
    The cutaneous arm, and the half of the syndrome that is often what brings a patient
    to attention. Lesions are neutrophilic - dermatoses characterised by neutrophilic
    pseudoabscesses - and the dominant forms are palmoplantar pustulosis and severe acne.
    Which of the two predominates is population-dependent rather than intrinsic to the
    disease. Skin lesions may precede, accompany or follow the skeletal ones, and can be
    absent altogether.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  downstream:
  - target: Chronic Relapsing Osteoarticular and Cutaneous Disease
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:23153960
    reference_title: The SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The SAHPO acronym identifies a syndrome encompassing a variety of
      osteoarticular disorders that are frequently accompanied by dermatoses
      characterized by neutrophilic pseudoabscesses, but can also occur in isolation."
    explanation: >-
      Establishes the neutrophilic character of the dermatoses, and records that the
      osteoarticular disease can occur without them.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The dermatological manifestations of SAPHO syndrome vary, with the most
      prevalent being severe acne and pustular eczema, especially palmoplantar
      pustulosis."
    explanation: Names the two dominant cutaneous forms.

- name: Chronic Relapsing Osteoarticular and Cutaneous Disease
  biological_scale: ORGANISM
  description: >-
    The clinical endpoint. The course is chronic and relapsing rather than monophasic or
    steadily progressive, and both the skeletal and dermatological arms are frequently
    the most debilitating features. Systemic inflammation adds constitutional symptoms -
    fever, weight loss, fatigue - and management is multidisciplinary because no single
    specialty sees the whole syndrome.
  evidence:
  - reference: PMID:37889264
    reference_title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other clinical findings include constitutional symptoms caused by systemic
      inflammation, such as fever, weight loss, and fatigue."
    explanation: Documents the systemic component of the clinical endpoint.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical course of SAPHO syndrome is often chronic and relapsing,
      significantly impacting patients"
    explanation: Establishes the chronic relapsing course that names this node.

mechanistic_hypotheses:
- hypothesis_group_id: canonical_autoinflammatory_cytokine_model
  hypothesis_label: Canonical Autoinflammatory Cytokine Model
  status: CANONICAL
  description: >-
    SAPHO arises from dysregulated innate immunity in a genetically predisposed host:
    neutrophil hyperactivity and excess IL-1 drive a self-amplifying TNF-alpha / IL-1beta
    / IL-6 / IL-8 / IL-23-IL-17 network that produces sterile osteitis, disordered bone
    remodelling and neutrophilic skin disease. The model is supported by the cytokine
    profile and by the therapeutic response to IL-1 and TNF blockade; its weakest point
    is that the predisposition itself has no identified genetic basis, so the model
    explains the amplification without explaining the initiation.
  evidence:
  - reference: PMID:37889264
    reference_title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Current evidence suggests that SAPHO results from a complex interplay
      between immune dysregulation, genetic susceptibility, and environmental factors."
    explanation: States the three-factor model this hypothesis group formalises.
  - reference: PMID:23153960
    reference_title: The SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This suggests that the pathogenesis of SAPHO syndrome is multifactorial,
      but this aspect remains poorly explored, although bacteria and immunological
      dysfunction are hypothesized to play a role."
    explanation: >-
      Supports the multifactorial framing while recording that it remains poorly
      explored, which is why the group is curated as canonical rather than established.

- hypothesis_group_id: emerging_cutibacterium_acnes_trigger_model
  hypothesis_label: Emerging Cutibacterium acnes Trigger Model
  status: EMERGING
  description: >-
    Low-grade intracellular persistence of Cutibacterium acnes in bone cells, rather than
    overt infection, supplies the recurrent NLRP3 inflammasome activation and IL-1beta
    release that drive the syndrome. This would make SAPHO a reactive osteitis in a
    susceptible host and would explain why the organism is culturable from lesions while
    antibiotics produce only transient benefit. It remains unproven: no controlled study
    establishes causation, and recovery of a commensal skin organism from a biopsy is
    equally consistent with contamination.
  evidence:
  - reference: PMID:28499891
    reference_title: "SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "As several auto-inflammatory bone disorders sharing overproduction of IL-1β
      can mimic SAPHO, this syndrome could partly depend on genetically encoded
      overproduction of IL-1β."
    explanation: >-
      Gives the proposal's own framing - a partial, IL-1beta-centred contribution rather
      than a claim that the organism causes the disease.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, infection with Propionibacterium acnes is believed to potentially
      trigger inflammatory responses by activating the immune system"
    explanation: >-
      A contemporary review carries the proposal forward, but with hedged language
      ("believed to potentially"), which is the level of confidence curated here.

phenotypes:
- category: Musculoskeletal
  name: Hyperostosis
  description: >-
    Excessive bone formation, classically at the sternoclavicular region. The H of the
    acronym and the feature that most distinguishes SAPHO bone disease from other sterile
    osteitis.
  phenotype_term:
    preferred_term: Hyperostosis
    term:
      id: HP:0100774
      label: Hyperostosis
  evidence:
  - reference: PMID:34967407
    reference_title: SAPHO syndrome and pustulotic arthro-osteitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Musculoskeletal manifestations, including osteitis, synovitis, and
      hyperostosis, are the hallmarks of the SAPHO syndrome and affect a variety of
      regions of the body."
    explanation: Establishes hyperostosis as a hallmark manifestation.

- category: Musculoskeletal
  name: Sterile Osteitis
  description: >-
    Inflammatory bone lesions with the imaging and histological appearance of
    osteomyelitis but no causative organism. Curated with the HPO osteomyelitis term
    because that is what the lesion looks like; the sterility that distinguishes it lives
    in this entry's descriptions and differentials, following the same convention used in
    the Chronic Recurrent Multifocal Osteomyelitis entry.
  phenotype_term:
    preferred_term: Sterile osteitis
    term:
      id: HP:0002754
      label: Osteomyelitis
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diagnosing SAPHO relies on the presence of clinical features (including
      sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion
      of differential diagnoses (such as infections, tumours, Langerhans cell
      histiocytosis)"
    explanation: Names sterile bone inflammation as a defining clinical feature.

- category: Musculoskeletal
  name: Synovitis
  description: >-
    Inflammation of the synovial membrane producing joint pain and swelling, the S of the
    acronym.
  phenotype_term:
    preferred_term: Synovitis
    term:
      id: HP:0100769
      label: Synovitis
  evidence:
  - reference: PMID:34967407
    reference_title: SAPHO syndrome and pustulotic arthro-osteitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Musculoskeletal manifestations, including osteitis, synovitis, and
      hyperostosis, are the hallmarks of the SAPHO syndrome and affect a variety of
      regions of the body."
    explanation: Establishes synovitis as a hallmark manifestation.

- category: Musculoskeletal
  name: Bone Pain
  description: >-
    Chronic pain in the affected bones, most often the anterior chest wall. It is the
    symptom treatment is aimed at, since no therapy is disease-modifying.
  phenotype_term:
    preferred_term: Bone pain
    term:
      id: HP:0002653
      label: Bone pain
    temporality: CHRONIC
  evidence:
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Skeletal symptoms typically include pain and swelling in the anterior chest
      wall and chronic pain, often associated with bone proliferation and inflammation
      near joints."
    explanation: Documents chronic bone pain and its anterior chest wall distribution.

- category: Musculoskeletal
  name: Sacroiliac Arthritis
  description: >-
    Axial involvement extending to the sacroiliac joints, part of the spondyloarthritis-like
    distribution of the skeletal disease.
  phenotype_term:
    preferred_term: Sacroiliac arthritis
    term:
      id: HP:0012317
      label: Sacroiliac arthritis
  evidence:
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Commonly, these bone alterations manifest in the anterior chest wall,
      including the sternum and clavicle, and extend to the cervical vertebrae and
      sacroiliac joints."
    explanation: Establishes sacroiliac joint involvement as part of the skeletal distribution.

- category: Dermatologic
  name: Palmoplantar Pustulosis
  description: >-
    Sterile pustular eruption of the palms and soles, the most characteristic cutaneous
    manifestation and the P of the acronym. In Japanese series it dominates the syndrome:
    more than 80% of reported cases are pustulotic arthro-osteitis.
  phenotype_term:
    preferred_term: Palmoplantar pustulosis
    term:
      id: HP:0100847
      label: Palmoplantar pustulosis
  evidence:
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The dermatological manifestations of SAPHO syndrome vary, with the most
      prevalent being severe acne and pustular eczema, especially palmoplantar
      pustulosis."
    explanation: Establishes palmoplantar pustulosis as a leading cutaneous manifestation.
  - reference: PMID:34967407
    reference_title: SAPHO syndrome and pustulotic arthro-osteitis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recent survey indicated that more than 80% of cases of SAPHO syndrome in
      Japan were PAO, originally proposed by Sonozaki et al. in 1981, whereas severe acne
      was the most commonly reported skin ailment amongst participants with SAPHO
      syndrome in Israel."
    explanation: >-
      Quantifies the population dependence of which cutaneous form predominates, which is
      why no single frequency band is asserted for either.

- category: Dermatologic
  name: Severe Acne
  description: >-
    Severe acneiform eruption, often resistant to conventional treatment, and the A of
    the acronym. It is the predominant cutaneous form in some populations where
    palmoplantar pustulosis is in others.
  phenotype_term:
    preferred_term: Severe acne
    term:
      id: HP:0001061
      label: Acne
    severity: SEVERE
  evidence:
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "acne (severe acneiform eruptions, often resistant to conventional
      treatments)"
    explanation: Gives the definitional description of the acne component of the acronym.

- category: Dermatologic
  name: Psoriasiform Skin Disease
  description: >-
    Psoriasis is among the common skin lesions in SAPHO, alongside acne. Curated against
    the HPO psoriasiform dermatitis term, which is the closest available concept - HPO has
    no plain "Psoriasis" class.
  phenotype_term:
    preferred_term: Psoriasis
    term:
      id: HP:0003765
      label: Psoriasiform dermatitis
  evidence:
  - reference: PMID:37889264
    reference_title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common skin lesions include psoriasis and acne, with hidradenitis
      suppurativa and neutrophilic dermatoses being less commonly seen."
    explanation: Names psoriasis among the common cutaneous manifestations.

- category: Dermatologic
  name: Hidradenitis Suppurativa
  description: >-
    A less common cutaneous association, curated because it places SAPHO in the wider
    family of follicular occlusion and neutrophilic skin disease.
  phenotype_term:
    preferred_term: Hidradenitis suppurativa
    term:
      id: HP:0040154
      label: Acne inversa
  evidence:
  - reference: PMID:37889264
    reference_title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Common skin lesions include psoriasis and acne, with hidradenitis
      suppurativa and neutrophilic dermatoses being less commonly seen."
    explanation: Names hidradenitis suppurativa as a less common cutaneous manifestation.

- category: Laboratory
  name: Elevated Acute Phase Reactants
  description: >-
    Raised ESR and CRP during active disease. There is no specific laboratory finding for
    SAPHO, so these support activity assessment rather than diagnosis.
  phenotype_term:
    preferred_term: Elevated erythrocyte sedimentation rate
    term:
      id: HP:0003565
      label: Elevated erythrocyte sedimentation rate
  evidence:
  - reference: PMID:37889264
    reference_title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, during active disease, there may be an increase in positive acute
      phase markers, such as erythrocyte sedimentation rate (ESR), C-reactive protein
      (CRP), complement levels, mild leukocytosis, and thrombocytosis."
    explanation: >-
      Documents the acute phase response, and in the same source the absence of any
      SAPHO-specific laboratory marker.

- category: Gastrointestinal
  name: Inflammatory Bowel Disease
  description: >-
    An extraosseous association that is structural rather than incidental: it has been
    recognised since the syndrome was first described and is written into the modified
    2003 Kahn diagnostic criteria. It is also one of the features SAPHO shares with
    spondyloarthritis.
  phenotype_term:
    preferred_term: Inflammatory bowel disease
    term:
      id: HP:0002037
      label: Inflammation of the large intestine
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An association with IBD—which are also associated to neutrophilic dermatoses and SpA—has been known since SAPHO’s description"
    explanation: Establishes the IBD association as recognised since the syndrome was first described.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "is also part of the modified 2003 Kahn’s criteria"
    explanation: >-
      Places the IBD association inside the diagnostic criteria, which is why it is
      curated as a phenotype rather than left to notes.

prevalence:
- population: Caucasian populations
  measure_type: UNKNOWN
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 10.0
  notes: >-
    Reported as "1 in 10,000". The two reviews carrying this figure trace it to the same
    source but label it differently - one calls it a frequency, the other an incidence -
    so measure_type is left UNKNOWN rather than guessed. Both state the true figure is
    unknown and likely higher because the disease is misdiagnosed or misclassified.
  evidence:
  - reference: PMID:37889264
    reference_title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SAPHO syndrome is rare, with a reported frequency of 1 in 10,000 in the
      Caucasian population."
    explanation: Source of the numeric estimate curated here.

- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: RARE
  notes: >-
    Estimated at below 1 in 10,000 in the explicit absence of reliable epidemiological
    data. Curated in the qualitative RARE band rather than a numeric Orphanet tier because
    the source gives only an upper bound.
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the absence of reliable epidemiological data, a prevalence of <1/10 000
      has been estimated."
    explanation: Source of the upper-bound estimate and of the caveat about data quality.

epidemiology:
- name: Age at onset and sex distribution
  description: >-
    Onset is typically in the third to fifth decade, which is the main axis separating
    SAPHO from paediatric CNO/CRMO in practice. A female predominance is reported, but it
    is not uniform: it is most evident in early-onset disease, and it inverts by cutaneous
    phenotype - severe acne is commoner in men, palmoplantar pustulosis and psoriasis in
    women. That is a second axis of population dependence alongside the geographic one,
    and it is the reason no single frequency band is asserted for either skin form.
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Disease onset is considered between the third and fifth decade of life"
    explanation: Source of the age-at-onset window, which previously appeared only as an unevidenced differential bullet.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "severe acne is more frequent in men, whereas palmoplantar pustulosis and psoriasis are more common in females"
    explanation: >-
      Documents the sex split by cutaneous phenotype, which qualifies any single statement
      of female predominance.
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "a female predilection (approximately 2.2:1) has been suggested"
    explanation: An independent estimate of the sex ratio from a systematic review.

- name: Comorbidity burden
  description: >-
    Comorbidity data are sparse and come largely from single groups, so these are reported
    rather than treated as established disease features. The pattern that does recur is
    cardiometabolic - hypertension is the commonest reported comorbidity and metabolic
    syndrome is more prevalent than in controls - alongside increased osteoporosis and a
    substantial fibromyalgia fraction, the latter mattering because it confounds the pain
    outcome that every SAPHO treatment is judged on.
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Przepiera-Będzak et al. reported hypertension (25%) as the most common
      comorbidity, followed by hypothyroidism and diabetes (9.6% each)"
    explanation: >-
      Gives the reported comorbidity frequencies. Graded PARTIAL because the source itself
      states that few data are available.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lastly, a recent Chinese study found an 18% prevalence of fibromyalgia,
      which was also associated to female sex and older age"
    explanation: >-
      Documents the fibromyalgia fraction, which is directly relevant to interpreting
      pain-based treatment response in this disease.

animal_models:
- name: PSTPIP2-knockout mouse
  species: Mouse
  genotype: Pstpip2 knockout (Pstpip2-/-)
  publication: PMID:25602062
  description: >-
    Germline Pstpip2 knockout mice develop paw swelling, synovitis, hyperostosis and
    osteitis with multifocal osteomyelitis, marked neutrophil and macrophage infiltration
    of bone, joint and skin, and elevated neutrophil-attracting chemokines and IL-1beta -
    a phenocopy of the human syndrome arising from a single defined gene.
  modeled_mechanisms:
  - target: Sterile Osteitis
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces sterile multifocal osteitis with synovitis and hyperostosis, together
      with the neutrophil infiltration and IL-1beta elevation that the human cytokine
      model predicts.
    limitations: >-
      The gene is the problem. A candidate-gene study of 38 human SAPHO patients found no
      association with PSTPIP2, so the mouse establishes that loss of one innate
      regulator can produce a SAPHO-like phenotype, not that this is the human mechanism.
      The bone phenotype also diverges in direction: the mouse develops profound
      osteolytic lesions with decreased bone volume density, whereas proliferative
      hyperostosis and osteosclerosis are the human radiological signature.
    readouts:
    - name: Neutrophil and macrophage infiltration of bone, joint and skin
      target: Sterile Osteitis
      direction: INCREASED
      interpretation: >-
        Cellular correlate of the sterile osteitis node, in the same three compartments
        the human syndrome involves.
      evidence:
      - reference: PMID:25602062
        reference_title: "Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Multifocal osteomyelitis was found in inflamed paws, with increased
          macrophage and marked neutrophil infiltrations in the bone, joint and skin."
        explanation: Reports the histological measurement behind this readout.
    - name: Tissue IL-1beta and neutrophil-attracting chemokines
      target: Sterile Osteitis
      direction: INCREASED
      interpretation: >-
        Confirms in a model system the two mediators the human cytokine hub and the
        neutrophil recruitment node depend on.
      evidence:
      - reference: PMID:25602062
        reference_title: "Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Neutrophil-attracting chemokines and IL-1β were markedly elevated in
          inflamed tissues."
        explanation: Reports the cytokine and chemokine measurement behind this readout.
    evidence:
    - reference: PMID:25602062
      reference_title: "Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "All Pstpip2(-/-) mice developed paw swelling, synovitis, hyperostosis and
        osteitis, resembling SAPHO syndrome, an inflammatory disorder of the bone, skin
        and joints."
      explanation: >-
        Supports treating this model as informative for the sterile osteitis node, with
        full penetrance of the SAPHO-like phenotype.
  evidence:
  - reference: PMID:20032092
    reference_title: "Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic studies of HLA genes have shown no role for these class II antigens,
      whereas studies of 2 mouse models (cmo and Lupo) point to a role of the PSTPIP2
      gene."
    explanation: >-
      Records why PSTPIP2 was the candidate worth testing in humans - two independent
      mouse models - which is the same reason this model is curated here.

definitions:
- name: Kahn and Benhamou diagnostic criteria for SAPHO syndrome
  definition_type: PHENOTYPE_ALGORITHM
  derivation_basis: ESTABLISHED_CRITERIA
  scope: DIAGNOSIS
  description: >-
    The two criteria sets in common use. Benhamou's were published in 1988, Kahn's in
    1994 and modified by the same author in 2003. All of them are built the same way -
    an osteoarticular manifestation paired with a form of SAPHO-typical skin disease,
    present or past - which is why an entry-level diagnosis can be made without any
    laboratory or histological finding.

    The consequential clause is in Kahn's set: chronic recurrent multifocal osteomyelitis
    in a child is by itself sufficient to diagnose SAPHO. That is what makes the boundary
    between this entry and Chronic Recurrent Multifocal Osteomyelitis a matter of
    convention rather than of biology, and it is the definitional basis of the nosology
    knowledge gap curated below.

    None of these criteria sets has been validated, and the contrast with the paediatric
    disease is instructive: CNO received jointly developed and externally validated
    EULAR/ACR classification criteria in 2025, while SAPHO has none.
  inclusion_criteria:
  - preferred_term: Osteoarticular manifestation with SAPHO-typical skin disease
    description: >-
      An osteoarticular manifestation - osteitis, hyperostosis or synovitis - paired with
      a form of SAPHO-typical skin disease, present or past. This pairing is the shared
      structure of every proposed criteria set.
  - preferred_term: Chronic recurrent multifocal osteomyelitis in a child
    description: >-
      Under Kahn's criteria this is by itself sufficient to diagnose SAPHO, with no skin
      disease required.
  - preferred_term: Inflammatory bowel disease association
    description: >-
      Incorporated into the modified 2003 Kahn criteria, which is what makes the IBD
      association structural to the diagnosis rather than incidental.
  exclusion_criteria:
  - preferred_term: Infectious osteomyelitis or spondylodiscitis
    description: Must be excluded; a monostotic lesion generally requires bone biopsy to do so.
  - preferred_term: Bone malignancy
    description: >-
      Osteosarcoma, Ewing sarcoma, bone metastasis, bone lymphoma and histiocytosis are
      all listed among the differentials to exclude.
  - preferred_term: Langerhans cell histiocytosis
    description: Named explicitly among the differentials to be excluded before diagnosis.
  validation_status:
    status: UNVALIDATED
    rationale: >-
      The source states directly that several diagnostic criteria sets have been proposed
      and none has been validated. There are consequently no externally validated
      diagnostic criteria or outcome measures in SAPHO, and no prospective randomised
      controlled trials - the second follows from the first.
    evidence:
    - reference: PMID:40004896
      reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Several subsets of diagnostic criteria (Table 3) have been proposed, but
        none of them have been validated."
      explanation: Directly establishes the unvalidated status recorded here.
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Several sets of diagnostic or classification criteria have been proposed, of
      which the ones developed by, Kahn et al (1994 modified in 2003) and Benhamou et al
      are most commonly used across the literature"
    explanation: Identifies the two criteria sets in common use and their revision history.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They are all based on the association between a bone and/or joint
      manifestation with a form of SAPHO"
    explanation: Gives the shared structure of every proposed criteria set.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "according to Kahn’s SAPHO diagnostic criteria, the presence of CRMO in children is sufficient for diagnosing SAPHO"
    explanation: >-
      The clause that makes the SAPHO/CNO boundary definitional rather than biological,
      and the evidence behind the nosology knowledge gap.
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Externally validated and internationally agreed diagnostic criteria or
      outcomes and, as a result, prospective randomised controlled trials in SAPHO are
      absent."
    explanation: >-
      States the downstream consequence of the unvalidated criteria - the absence of any
      randomised trial evidence in this disease.

diagnosis:
- name: Diagnosis of Exclusion
  description: >-
    There is no specific laboratory finding for SAPHO and no validated criteria set, so
    diagnosis rests on recognising a compatible clinical picture and excluding the
    alternatives. Infection and malignancy are the two that matter, and the monostotic
    lesion is the hard case - a single sclerotic or lytic lesion without skin disease is
    not distinguishable from osteomyelitis or a bone tumour on imaging alone.
  diagnosis_term:
    preferred_term: diagnosis of exclusion
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diagnosing SAPHO relies on the presence of clinical features (including
      sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion
      of differential diagnoses (such as infections, tumours, Langerhans cell
      histiocytosis)"
    explanation: States the exclusion-based structure of the diagnostic approach.
  - reference: PMID:37889264
    reference_title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is no specific laboratory finding for SAPHO syndrome."
    explanation: >-
      Establishes the absence of a diagnostic biomarker, which is a property of the
      disease rather than a gap in this entry's sourcing.

- name: Magnetic Resonance Imaging
  description: >-
    Proposed as the gold standard modality, because it detects bone marrow oedema - the
    osteitis itself - as well as erosions and ankylosis. The case for it over plain films
    is quantitative and stark: at early stages conventional radiography shows only 16% of
    the lesions MRI sees, so a normal radiograph does not exclude active disease.
  diagnosis_term:
    preferred_term: Magnetic Resonance Imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Magnetic resonance imaging (MRI) has been suggested as a gold standard
      diagnostic modality for its ability to detect osteitis (bone marrow oedema) as well
      as structural lesions, like erosions and ankyloses"
    explanation: Establishes MRI as the proposed reference modality and what it detects.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fritz et al. found that, at early stages, conventional radiography only
      shows 16% of the lesions seen on MRI"
    explanation: Quantifies the sensitivity gap that makes MRI rather than radiography the reference test.

- name: Bone Scintigraphy
  description: >-
    Whole-skeleton survey, which is what makes it useful in a multifocal disease: it
    assesses every involved site at once and helps rule out malignancy and infection. Its
    contribution to positive diagnosis is the bull's head sign - symmetrical uptake across
    the sternoclavicular region - which is characteristic of SAPHO but insensitive, so its
    absence carries little weight.
  diagnosis_term:
    preferred_term: Bone Scan
    term:
      id: NCIT:C17646
      label: Bone Scan
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bone scintigraphy has many advantages, as it can assess multiple involved
      sites, as well as rule out malignancy and infection."
    explanation: States the whole-skeleton and exclusion roles of scintigraphy.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sign, seen with this technique, describes a symmetric uptake in the sternoclavicular region; it is characteristic but not highly sensitive"
    explanation: >-
      Describes the bull's head sign and records that it is characteristic but not
      sensitive - which is why it is graded PARTIAL as a diagnostic test.

- name: Bone Biopsy
  description: >-
    Reserved for the case the imaging cannot settle. A monostotic lesion is the specific
    indication, because that is where the infectious and neoplastic hypotheses cannot be
    excluded on distribution.
  diagnosis_term:
    preferred_term: Biopsy of Bone
    term:
      id: NCIT:C51927
      label: Biopsy of Bone
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the infectious and neoplastic hypothesis should be always ruled out,
      especially when confronting a monostotic lesion, by means of a bone biopsy."
    explanation: Names the indication for biopsy and the two hypotheses it is used to exclude.

- name: Multimodal Imaging Assessment
  description: >-
    No single modality does the whole job. Radiographs and CT show structural change,
    scintigraphy surveys the skeleton, and MRI, whole-body MRI and PET-CT detect lesions
    before structural damage and report soft tissue involvement.
  diagnosis_term:
    preferred_term: Positron Emission Tomography
    term:
      id: NCIT:C17007
      label: Positron Emission Tomography
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Alongside radiographic imaging (plain radiographs, CT), bone scintigraphy,
      MRI, whole-body MRI and positron emission tomography (PET) CT are considered key
      diagnostic tools."
    explanation: Names the full set of modalities considered key to diagnosis.
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI and PET CT enable early detection of bone lesions prior to structural
      damage, and provide information on soft tissue involvement."
    explanation: Distinguishes what the cross-sectional modalities add over radiographs and CT.

treatments:
- name: Nonsteroidal Anti-Inflammatory Therapy
  description: >-
    First-line, together with analgesics. As in chronic nonbacterial osteomyelitis, no
    agent is licensed for SAPHO and every treatment below is used off-label; there are no
    prospective randomised controlled trials in this disease at all, because there are no
    externally validated diagnostic criteria or outcome measures to run them against.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: nonsteroidal anti-inflammatory drug
      term:
        id: NCIT:C257
        label: Nonsteroidal Antiinflammatory Drug
  target_mechanisms:
  - target: Sterile Osteitis
    treatment_effect: INHIBITS
    description: >-
      Suppresses the inflammatory bone lesion symptomatically without addressing the
      upstream innate dysregulation.
    evidence:
    - reference: PMID:23153960
      reference_title: The SAPHO syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "They include nonsteroidal anti-inflammatory drugs and analgesics as
        first-line agents."
      explanation: Establishes NSAIDs as the first-line agents this link describes.
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Externally validated and internationally agreed diagnostic criteria or
      outcomes and, as a result, prospective randomised controlled trials in SAPHO are
      absent."
    explanation: >-
      Establishes the evidence-base limitation that qualifies every treatment curated in
      this entry.

- name: TNF-alpha Blockade
  description: >-
    The biologic of first choice in conventional-treatment-refractory disease. In a
    systematic review of 66 biologic-treated cases, anti-TNF agents gave the highest
    response rate in bone and joint manifestations of any class. The caveat is
    compartment-specific and paradoxical: anti-TNF treatment can itself provoke skin
    lesions in some patients.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: infliximab
      term:
        id: NCIT:C1789
        label: Infliximab
    - preferred_term: adalimumab
      term:
        id: NCIT:C65216
        label: Adalimumab
  target_mechanisms:
  - target: Pro-Inflammatory Cytokine Amplification
    treatment_effect: INHIBITS
    description: >-
      Removes TNF-alpha from the self-amplifying cytokine hub, which is where its effect
      on both the bone and the skin arms originates.
    evidence:
    - reference: PMID:29773231
      reference_title: "Biologics in SAPHO syndrome: A systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Data support a positive effect of anti-TNF treatment in SAPHO with a
        response rate in bone and joint manifestations of 93.3%."
      explanation: Quantifies the osteoarticular response rate that grounds this treatment link.
  evidence:
  - reference: PMID:29773231
    reference_title: "Biologics in SAPHO syndrome: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In SAPHO patients not responding to conventional treatment, TNF blockers
      appear to be the first choice."
    explanation: Establishes anti-TNF as first-line biologic therapy.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, other research has revealed that anti-TNF-α treatments can
      provoke skin lesions in some patients, highlighting the influential role of TNF-α
      in these dermatological manifestations."
    explanation: >-
      Records the paradoxical cutaneous reaction, which is why the osteoarticular and
      dermatological responses to this agent must be assessed separately.

- name: IL-1 Blockade
  description: >-
    Effective in the musculoskeletal compartment and, on the available data, not in the
    skin. That dissociation is mechanistically informative rather than a limitation of the
    evidence: it argues that the bone and skin arms of the syndrome do not depend on the
    same cytokine to the same degree.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: anakinra
      term:
        id: NCIT:C38717
        label: Anakinra
  target_mechanisms:
  - target: Pro-Inflammatory Cytokine Amplification
    treatment_effect: INHIBITS
    description: >-
      Blocks IL-1 receptor signalling within the cytokine hub. The response supports
      IL-1 as a load-bearing component of the osteoarticular arm specifically.
    evidence:
    - reference: PMID:29773231
      reference_title: "Biologics in SAPHO syndrome: A systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Data related to IL-1 inhibition in SAPHO are encouraging with most
        patients exhibiting a significant response in musculoskeletal manifestations
        (6/7, 85.7%). However, IL-1 inhibition is not effective in skin manifestations."
      explanation: >-
        Gives both halves of the dissociation - musculoskeletal response and cutaneous
        non-response - from a single systematic review.

- name: IL-17 and IL-23 Blockade
  description: >-
    The mirror image of IL-1 blockade: efficacy concentrated in the skin, with little
    consistent osteoarticular benefit. Two independent sources report the same asymmetry,
    and both note paradoxical psoriasis flares as a class effect.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: secukinumab
      term:
        id: NCIT:C152315
        label: Secukinumab
    - preferred_term: ustekinumab
      term:
        id: NCIT:C84237
        label: Ustekinumab
  target_mechanisms:
  - target: Neutrophilic Skin Inflammation
    treatment_effect: INHIBITS
    description: >-
      Interrupts the IL-23/IL-17 arm of the cytokine hub, which is the arm the cutaneous
      manifestations track most closely.
    evidence:
    - reference: PMID:39286247
      reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "One particular study on patients with SAPHO syndrome showed that
        treatment with Secukinumab, an IL-17 inhibitor, significantly alleviated skin
        lesions and joint pain, indicating a crucial role of IL-17 in the associated skin
        manifestations."
      explanation: Supports IL-17 blockade acting on the cutaneous node.
  evidence:
  - reference: PMID:29773231
    reference_title: "Biologics in SAPHO syndrome: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Data related to IL-17 blockade indicate efficacy in skin disease with 4/7
      patients responding (57.1%). Joint/bone manifestations improved in 3/8 patients
      (37.5%)."
    explanation: Quantifies the skin-versus-bone asymmetry for IL-17 blockade.
  - reference: PMID:28532819
    reference_title: IL-23/Th17 targeted therapies in SAPHO syndrome. A case series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Regarding the rheumatic symptoms, no major improvement was obvious under
      any of the six treatment courses."
    explanation: >-
      An independent case series reporting no major rheumatic improvement across six
      courses, corroborating the compartment asymmetry.
  - reference: PMID:28532819
    reference_title: IL-23/Th17 targeted therapies in SAPHO syndrome. A case series.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "No particular safety concerns were reported, except cases of paradoxical
      psoriasis flare in one under ustekinumab and the other case under secukinumab."
    explanation: Documents paradoxical psoriasis flare with both agents in this class.

- name: Bisphosphonate Therapy
  description: >-
    A treatment chosen for the specific shape of this disease. SAPHO combines increased
    bone remodelling with inflammatory osteitis, and bisphosphonates act on both - an
    antiosteoclastic effect and an anti-inflammatory one - which is why they are used
    here rather than as generic bone-protective agents.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pamidronate
      term:
        id: CHEBI:7903
        label: pamidronate
    - preferred_term: zoledronic acid
      term:
        id: CHEBI:46557
        label: zoledronic acid
  target_mechanisms:
  - target: Bone Remodeling Imbalance
    treatment_effect: MODULATES
    description: >-
      Acts directly on the remodelling node by suppressing osteoclast activity, while its
      anti-inflammatory action reaches the osteitis.
    evidence:
    - reference: PMID:12184437
      reference_title: Pamidronate treatment in SAPHO syndrome.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "SAPHO syndrome is characterized by both increased bone remodeling and
        inflammatory osteitis, indicating that it may respond favorably to pamidronate's
        dual mechanism of action."
      explanation: States the dual-mechanism rationale that grounds this treatment link.
  - target: Neutrophilic Skin Inflammation
    treatment_effect: INHIBITS
    description: >-
      A contested link, curated because it cuts against this entry's own compartment
      argument. One open-label study reported pamidronate preventing recurrence of
      pustulosis in 9 of 10 patients refractory to several systemic agents - a
      bone-directed drug acting on skin. Concomitant NSAIDs were permitted, and other
      studies did not reproduce the effect, so the link is asserted weakly rather than
      dropped.
    evidence:
    - reference: PMID:38151265
      reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Somewhat unexpectedly, one open-label study also reported beneficial
        effects of pamidronate on skin lesions, preventing recurrence of pustulosis in
        9/10 patients (90%)"
      explanation: The positive cutaneous result, from a single uncontrolled open-label study.
    - reference: PMID:38151265
      reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
      supports: REFUTE
      evidence_source: HUMAN_CLINICAL
      snippet: "However, NSAID use was permitted as concomitant treatment, which may have
        had additional effects."
      explanation: >-
        The confound that prevents attributing the cutaneous benefit to pamidronate, from
        the same systematic review.
    - reference: PMID:38151265
      reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
      supports: REFUTE
      evidence_source: HUMAN_CLINICAL
      snippet: "Others did not confirm effects on the skin."
      explanation: Records the failure to reproduce, which is why this link is curated as contested.
  evidence:
  - reference: PMID:12184437
    reference_title: Pamidronate treatment in SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Four of the five patients had a response after 1 week."
    explanation: >-
      The observed response, from an uncontrolled series of five refractory patients -
      the scale of evidence available for this indication.
  - reference: PMID:39286247
    reference_title: The role of cytokines in the pathogenesis of SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Recent studies have underscored the effectiveness of bisphosphonates, such
      as zoledronic acid, in alleviating pain and reducing inflammatory lesions in
      patients with SAPHO syndrome."
    explanation: Corroborates the class effect with a second-generation agent.

- name: Corticosteroids and Conventional DMARDs
  description: >-
    Escalation between NSAIDs and biologics. The honest summary of this tier is that it
    helps some patients and not others, which is itself the evidence cited for the
    pathogenesis being multifactorial.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: prednisolone
      term:
        id: CHEBI:8378
        label: prednisolone
    - preferred_term: methotrexate
      term:
        id: CHEBI:44185
        label: methotrexate
    - preferred_term: sulfasalazine
      term:
        id: CHEBI:9334
        label: sulfasalazine
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sulfasalazine (SSZ) reduce proinflammatory cytokine expression."
    explanation: >-
      Names sulfasalazine among the conventional DMARDs used here, with the cytokine
      mechanism that places it against this entry's pathograph hub.
  - reference: PMID:23153960
    reference_title: The SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Systemic corticosteroids, disease-modifying anti-rheumatic drugs,
      biologicals targeting tumor necrosis factor alpha and interleukin-1, and
      bisphosphonates have all been beneficial in some patients, but ineffective in
      others."
    explanation: >-
      Documents the inconsistent response across every drug class, which is the
      observation this tier is curated against.

- name: Antibiotic Therapy
  description: >-
    Used on the reasoning that C. acnes drives the disease. It is curated because its
    partial failure is mechanistically informative: benefit is transient and incomplete,
    which is a substantial part of the argument against overt infection as the cause. A
    corollary in the clinical literature runs the other way - recognising SAPHO promptly
    prevents patients being given long-term antibiotics they do not need.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Antibiotic Therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
    therapeutic_agent:
    - preferred_term: doxycycline
      term:
        id: CHEBI:50845
        label: doxycycline
    - preferred_term: azithromycin
      term:
        id: CHEBI:2955
        label: azithromycin
  target_mechanisms:
  - target: Cutibacterium acnes Intraosseous Persistence
    treatment_effect: INHIBITS
    description: >-
      Targets the hypothesised persistent organism. The incompleteness of the response is
      the informative part, and is one reason the C. acnes model is curated as emerging
      rather than canonical.
    evidence:
    - reference: PMID:28499891
      reference_title: "SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Overt infection by Propionibacterium acnes is lacking in many SAPHO
        syndromes, and antibiotics have only a transient and incomplete effect, either in
        SAPHO syndrome or acne."
      explanation: Records the transient, incomplete antibiotic effect this link is curated around.
  evidence:
  - reference: PMID:23153960
    reference_title: The SAPHO syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The early recognition, diagnosis, and prompt treatment of SAPHO syndrome
      can prevent the unnecessary use of long-term antibiotics or invasive procedures"
    explanation: >-
      Frames prolonged antibiotic exposure as a harm of delayed diagnosis rather than as
      standard therapy.

- name: JAK Inhibition
  description: >-
    The newest class in use, and the one that most complicates the compartment story.
    Two pilot studies of tofacitinib disagree about bone: one reported a bone response in
    9 of 12 patients alongside skin improvement, the other found significant benefit for
    nail and palmoplantar lesions with no clear osteoarticular efficacy - reduced pain but
    no MRI improvement. Both are small, open-label and unrandomised. Curated because a
    class with published prospective data belongs in the entry, and because the
    disagreement bears directly on whether the bone and skin compartments are separable.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tofacitinib
      term:
        id: CHEBI:71200
        label: tofacitinib
  target_mechanisms:
  - target: Pro-Inflammatory Cytokine Amplification
    treatment_effect: INHIBITS
    description: >-
      Blocks JAK-dependent signalling downstream of several of the cytokines in the hub at
      once, rather than neutralising a single one - which is the mechanistic reason it is
      a candidate for the compartment asymmetry the single-cytokine agents show.
    evidence:
    - reference: PMID:38151265
      reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "One study investigated effects of the JAK inhibitor tofacitinib on
        dermatological manifestations in 13 Asian female SAPHO patients (12 weeks of 5 mg
        tofacitinib, twice daily)."
      explanation: Identifies the prospective open-label study behind this treatment entry.
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Results were positive with significant benefit for nail lesions,
      palmoplantar pustulosis and associated quality of life."
    explanation: Reports the cutaneous benefit observed in that study.
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: "While a reduction of systemic inflammatory parameters was observed (CRP and
      ESR), no information was provided on bone involvement."
    explanation: >-
      Records that the study reported nothing on the osteoarticular compartment, so it
      cannot be read either way on bone.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Li et al. treated 12 patients; 9 had a bone response and 7/8 experienced an
      improvement in skin manifestations (6 PPP and 1 acne)."
    explanation: >-
      The second pilot study, reporting a bone response - which is the datum that
      disagrees with the first and is why this class is curated as unresolved on bone.

differential_diagnoses:
- name: Bacterial osteomyelitis
  description: >-
    The differential the sterile osteitis is defined against, and a formal exclusion in
    every proposed criteria set. Imaging and histology can be indistinguishable, and the
    cost of error runs both ways - antibiotics and surgery for an inflammatory disease,
    or immunosuppression for an untreated infection.
  distinguishing_features:
  - No causative organism accounts for the lesions in SAPHO
  - Antibiotics give only transient and incomplete benefit in SAPHO
  - Anterior chest wall hyperostosis and accompanying neutrophilic skin disease are not features of bacterial osteomyelitis
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diagnosing SAPHO relies on the presence of clinical features (including
      sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion
      of differential diagnoses (such as infections, tumours, Langerhans cell
      histiocytosis)"
    explanation: Establishes infection as a formal exclusion in the diagnostic approach.

- name: Bone malignancy
  description: >-
    Primary bone tumours and metastatic disease can produce sclerotic or lytic lesions
    with pain in the same distribution. Formally excluded before a SAPHO diagnosis is
    made, and the reason biopsy is often performed.
  distinguishing_features:
  - Formal exclusion in the clinical diagnostic approach
  - SAPHO lesions are typically multifocal with a relapsing rather than progressive course
  - Accompanying neutrophilic skin disease points away from malignancy
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diagnosing SAPHO relies on the presence of clinical features (including
      sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion
      of differential diagnoses (such as infections, tumours, Langerhans cell
      histiocytosis)"
    explanation: Names tumours as a formal exclusion.

- name: Langerhans cell histiocytosis
  description: >-
    A specific named exclusion rather than a generic one. It produces multifocal bone
    lesions with skin involvement, which is precisely the SAPHO pattern, so it is
    excluded on histology rather than on distribution.
  distinguishing_features:
  - Named explicitly among the differentials to be excluded
  - Distinguished by lesional histology rather than by lesion distribution
  evidence:
  - reference: PMID:38151265
    reference_title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "diagnosing SAPHO relies on the presence of clinical features (including
      sterile bone inflammation, arthritis, inflammatory skin disease) and the exclusion
      of differential diagnoses (such as infections, tumours, Langerhans cell
      histiocytosis)"
    explanation: Names Langerhans cell histiocytosis as a specific exclusion.

- name: Chronic nonbacterial osteomyelitis of childhood
  description: >-
    Not straightforwardly a differential. CNO/CRMO shares the sterile multifocal osteitis
    and can share the skin manifestations, and whether it is a distinct condition or the
    paediatric expression of the same disease is actively debated. Kahn's criteria treat
    the presence of CRMO in a child as sufficient for a SAPHO diagnosis, which makes the
    boundary a matter of convention rather than of biology. Curated as a differential
    because dismech holds a separate entry for it.
  distinguishing_features:
  - CNO/CRMO presents in children and adolescents; SAPHO onset is typically the third to fifth decade
  - Anterior chest wall hyperostosis is more characteristic of adult SAPHO
  - Under Kahn's criteria, CRMO in a child is itself sufficient to diagnose SAPHO
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, there is an ongoing debate about whether SAPHO syndrome and CNO
      are distinct conditions or simply represent different manifestations of the same
      disease depending on the age at onset"
    explanation: >-
      Records the unresolved nosology directly, which is why this is curated as a
      contested boundary rather than a clean differential.

- name: Monogenic autoinflammatory bone diseases
  description: >-
    The mechanistically informative differential group, and the one that shows what SAPHO
    would look like if it had a single cause. PAPA, DIRA, DITRA and Majeed syndrome each
    produce sterile osteitis with neutrophilic skin disease from a defined gene, and each
    has a correspondingly clean cytokine dependency. SAPHO has neither - which is exactly
    the contrast that makes its heterogeneous treatment response the thing a mechanistic
    account has to explain.
  distinguishing_features:
  - Each has an identified causal gene; SAPHO has none, and its three strongest candidates were excluded in a human cohort
  - Onset is typically neonatal or paediatric rather than the third to fifth decade
  - Cytokine dependency is defined and single-agent responsive, unlike SAPHO's heterogeneous response across every drug class
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Monogenic autoinflammatory bone diseases: PAPA syndrome, DIRA syndrome,
      deficiency of interleukin-36 receptor antagonist (DITRA) syndrome, or Majeed
      syndrome."
    explanation: Names the four monogenic differentials to be considered.

- name: Spondyloarthritis
  description: >-
    Overlaps SAPHO on almost every clinical axis - peripheral arthritis, enthesitis,
    sacroiliac and spinal involvement, psoriasis, inflammatory bowel disease - which is
    why the two are periodically proposed as the same family. The discriminator is
    genetic and clean: SAPHO shows no increase in HLA-B27 frequency, unlike SpA. MRI adds
    a second: SAPHO has lower rates of sacroiliitis and erosion but more anterior chest
    wall involvement.
  distinguishing_features:
  - SAPHO shows no increased HLA-B27 frequency, unlike spondyloarthritis
  - Anterior chest wall involvement is commoner in SAPHO; sacroiliitis and erosions less common
  - Hyperostosis and osteitis rather than a purely erosive or ankylosing pattern
  evidence:
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "genetic reports on SAPHO syndrome did not show an increase in HLA-B27
      frequency, unlike in SpA"
    explanation: The genetic discriminator separating SAPHO from spondyloarthritis.
  - reference: PMID:40004896
    reference_title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The former, in fact, had lower incidence of both sacroiliitis and erosions,
      as well as a higher incidence of anterior chest wall involvement."
    explanation: The imaging discriminator, from a direct SAPHO-versus-SpA MRI comparison.

discussions:
- discussion_id: gap_sapho_cutibacterium_acnes_trigger_or_contaminant
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Cutibacterium acnes Intraosseous Persistence
  - mechanistic_hypotheses#emerging_cutibacterium_acnes_trigger_model
  prompt: >-
    Is Cutibacterium acnes recovered from SAPHO bone lesions a causal trigger of the
    osteitis, or a commensal contaminant of the biopsy?
  rationale: >-
    Every element of the argument is currently compatible with both answers. C. acnes is
    a potent NLRP3 inflammasome activator and would supply the IL-1beta the rest of the
    mechanism requires, which is the case for causation. Against it: overt infection is
    absent in many patients, antibiotics produce only transient and incomplete benefit,
    and C. acnes is the commonest contaminant of any biopsy taken through skin - so
    recovery from a lesion is weak evidence either way. The question matters beyond
    taxonomy, because the two answers imply different diseases. If the organism is
    causal, SAPHO is a reactive osteitis in a susceptible host and antimicrobial strategy
    is undertreated; if it is a contaminant, the antibiotic exposure many patients
    receive is pure harm, which the clinical literature already flags as a consequence of
    delayed diagnosis.
  proposed_experiments:
  - experiment_id: exp_sapho_acnes_quantitative_culture_versus_controls
    name: Quantify C. acnes in SAPHO bone lesions against contamination-matched controls
    description: >-
      Compare organism burden in SAPHO lesional bone against two control sets that the
      existing literature lacks: unaffected bone from the same patients, and bone from
      non-SAPHO patients biopsied through skin by the same route. Contamination predicts
      similar low-level recovery across all three; a causal role predicts enrichment in
      lesional bone specifically. Pair this with intracellular localisation in bone cells,
      since the hypothesis is persistence rather than infection and a purely extracellular
      or surface-associated organism would not support it.
    would_support:
    - pathophysiology#Cutibacterium acnes Intraosseous Persistence
    supporting_outcome:
    - >-
      Organism burden is significantly enriched in lesional bone relative to both control
      sets, with demonstrable intracellular localisation in bone-resident cells.
    would_refute:
    - pathophysiology#Cutibacterium acnes Intraosseous Persistence
    refuting_outcome:
    - >-
      Recovery rates are indistinguishable across lesional bone, unaffected bone and
      non-SAPHO skin-route biopsies, consistent with contamination during sampling.

- discussion_id: gap_sapho_cno_nosology_one_disease_or_two
  kind: KNOWLEDGE_GAP
  attaches_to:
  - disease#SAPHO Syndrome
  - differential_diagnoses#Chronic nonbacterial osteomyelitis of childhood
  prompt: >-
    Are SAPHO syndrome and paediatric chronic nonbacterial osteomyelitis two diseases, or
    one disease observed at two ages?
  rationale: >-
    The debate is live in the current literature rather than settled by convention.
    Kahn's criteria already treat CRMO in a child as sufficient to diagnose SAPHO; CNO can
    carry the same skin manifestations and the same IBD association; and adult CNO without
    skin disease is described. What separates them in practice is age at onset and the
    prominence of anterior chest wall hyperostosis, neither of which is obviously a
    difference in mechanism. dismech currently holds two entries, so the answer is not
    merely nosological here - it determines whether this entry and Chronic Recurrent
    Multifocal Osteomyelitis should eventually be one entry with age-stratified subtypes.
  proposed_experiments:
  - experiment_id: exp_sapho_cno_joint_molecular_stratification
    name: Jointly stratify SAPHO and CNO cohorts on innate signalling and treatment response
    description: >-
      Profile monocyte and neutrophil innate signalling, cytokine output and treatment
      response across an age-spanning cohort recruited under both diagnoses, and test
      whether the resulting clusters track diagnosis or track age. If clusters cut across
      both labels, the two are one disease and the diagnostic boundary is an artefact of
      which specialty sees the patient. If they separate cleanly by diagnosis
      independently of age, the entities are distinct and the shared features are
      convergent.
    would_support:
    - disease#SAPHO Syndrome
    supporting_outcome:
    - >-
      Molecular and treatment-response clusters separate SAPHO from CNO independently of
      age at onset, supporting two distinct entities.
    would_refute:
    - disease#SAPHO Syndrome
    refuting_outcome:
    - >-
      Clusters cut across the two diagnostic labels and track age or skin phenotype
      instead, indicating a single disease with age-dependent expression.

- discussion_id: gap_sapho_compartment_specific_cytokine_dependency
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Pro-Inflammatory Cytokine Amplification
  prompt: >-
    Why do the bone and skin compartments of SAPHO depend on different cytokines, and can
    that dissociation be used to choose therapy?
  rationale: >-
    The treatment data contain a clean, reproducible asymmetry that no current mechanistic
    account explains. IL-1 blockade produces musculoskeletal responses and is reported
    ineffective in skin; IL-17/IL-23 blockade does the reverse, improving skin while
    leaving rheumatic symptoms largely unchanged; anti-TNF works in bone and joint but can
    paradoxically provoke skin lesions. If SAPHO were a single cytokine-driven process, a
    given blockade should move both arms together. That it does not suggests the syndrome
    is two partially independent inflammatory programmes sharing an upstream innate
    defect - which would also explain why skin disease can be absent entirely, and why
    combination or compartment-directed therapy is not currently rational to prescribe
    because nobody has tested it.

    Two results cut against a clean dissociation and are curated rather than set aside.
    An open-label study reported pamidronate - a bone-directed agent - preventing
    recurrence of pustulosis in 9 of 10 refractory patients, though concomitant NSAIDs
    were permitted and others did not reproduce it. And the two tofacitinib pilot studies
    disagree with each other on bone, one reporting a response in 9 of 12 patients and the
    other reporting none. A JAK inhibitor acting on several hub cytokines at once is the
    natural test of whether the compartments are separable, and the existing data are too
    small and too discordant to answer it.
  proposed_experiments:
  - experiment_id: exp_sapho_paired_bone_skin_cytokine_profiling
    name: Paired lesional bone and skin cytokine profiling before and after single-agent blockade
    description: >-
      Sample lesional bone and lesional skin from the same patients before and after a
      defined course of single-agent IL-1, TNF or IL-17 blockade, and measure
      compartment-resolved cytokine and cellular profiles alongside compartment-specific
      clinical response. The discriminating result is whether the non-responding
      compartment shows an unchanged local cytokine profile - true independence - or a
      changed profile without clinical response, which would instead implicate established
      structural damage rather than ongoing cytokine drive.
    would_support:
    - pathophysiology#Pro-Inflammatory Cytokine Amplification
    supporting_outcome:
    - >-
      Blockade suppresses its target cytokine in both compartments but only the responding
      compartment shows resolution, locating the dissociation downstream of the shared hub.
    would_refute:
    - pathophysiology#Pro-Inflammatory Cytokine Amplification
    refuting_outcome:
    - >-
      Each compartment shows an independent cytokine profile unaffected by blockade of the
      other's dominant mediator, indicating two separate programmes rather than one hub.

notes: >-
  Relationship to Chronic Recurrent Multifocal Osteomyelitis. dismech holds a separate
  entry for paediatric CNO/CRMO, and that entry does not mention SAPHO. The two are
  curated separately here because MONDO keeps SAPHO as a sibling under autoinflammatory
  syndrome rather than under CRMO, and because SAPHO adds the cutaneous and anterior
  chest wall axes. That separation is a curation convention, not a settled biological
  claim - the literature actively debates it, and the debate is curated as a knowledge
  gap rather than resolved by the file layout.

  Category is Complex rather than Mendelian or Autoimmune. No causal gene is established:
  the strongest candidates, PSTPIP2, NOD2 and LPIN2, were tested together in a human
  cohort and none was associated. Autoimmune was rejected because current reviews
  explicitly weigh the question and conclude autoinflammatory, on the basis of neutrophil
  hyperactivity, reduced NK cells, high IL-1 and the response to IL-1 blockade. No
  genetic section is curated for this reason - listing PSTPIP2 as a disease gene would
  assert exactly what the cited study refutes. The gene appears instead as the genotype of
  the mouse model, where the human negative result is recorded as that model's limitation.

  Prevalence is curated as two records because the sources are not comparable. One reports
  1 in 10,000 in Caucasian populations - labelled a frequency in one review and an
  incidence in another, hence measure_type UNKNOWN - and the other gives an upper bound of
  below 1 in 10,000 in the explicit absence of reliable epidemiological data. A third
  source states plainly that the prevalence remains unavailable. No figure is treated as
  authoritative.

  No frequency bands are asserted for the cutaneous phenotypes. Which form predominates
  is population-dependent: more than 80% of Japanese cases are pustulotic arthro-osteitis,
  while severe acne is the commonest skin finding in an Israeli series. A single band
  would misrepresent that. Dermatological involvement overall is reported in 60-90% of
  cases, which is recorded in the description rather than attached to any one phenotype.

  No conforms_to is declared. No module in kb/modules/ covers sterile IL-1-driven
  osteitis, and the Chronic Recurrent Multifocal Osteomyelitis entry declares none either.
  If such a module is created later, both entries are candidates to conform to it.

  No comorbidities section exists on the Disease class, so the reported cardiometabolic,
  osteoporosis and fibromyalgia associations are curated under epidemiology rather than
  invented as a new slot. Inflammatory bowel disease is curated as a phenotype instead,
  because it is written into the modified 2003 Kahn criteria and so is structural to the
  diagnosis rather than an incidental association - the same placement the Chronic
  Recurrent Multifocal Osteomyelitis entry uses.

  Antibiotic therapy is curated as a treatment despite working poorly. Its partial failure
  is evidence bearing on the C. acnes hypothesis, and prolonged antibiotic exposure is a
  documented harm of delayed diagnosis - both of which are lost if the entry lists only
  effective therapies.

references:
- reference: PMID:37889264
  title: "SAPHO syndrome: current clinical, diagnostic and treatment approaches."
- reference: PMID:39286247
  title: The role of cytokines in the pathogenesis of SAPHO syndrome.
- reference: PMID:38151265
  title: "Treatment and monitoring of SAPHO syndrome: a systematic review."
- reference: PMID:40004896
  title: "What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review."
- reference: PMID:34967407
  title: SAPHO syndrome and pustulotic arthro-osteitis.
- reference: PMID:23153960
  title: The SAPHO syndrome.
- reference: PMID:29773231
  title: "Biologics in SAPHO syndrome: A systematic review."
- reference: PMID:28532819
  title: IL-23/Th17 targeted therapies in SAPHO syndrome. A case series.
- reference: PMID:12184437
  title: Pamidronate treatment in SAPHO syndrome.
- reference: PMID:25602062
  title: "Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice."
- reference: PMID:20032092
  title: "Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes."
- reference: PMID:28499891
  title: "SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes."

📚

References & Deep Research

References

12

PMID:37889264

SAPHO syndrome: current clinical, diagnostic and treatment approaches.

No top-level findings curated for this source.

PMID:39286247

The role of cytokines in the pathogenesis of SAPHO syndrome.

No top-level findings curated for this source.

PMID:38151265

Treatment and monitoring of SAPHO syndrome: a systematic review.

No top-level findings curated for this source.

PMID:40004896

What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review.

No top-level findings curated for this source.

PMID:34967407

SAPHO syndrome and pustulotic arthro-osteitis.

No top-level findings curated for this source.

PMID:23153960

The SAPHO syndrome.

No top-level findings curated for this source.

PMID:29773231

Biologics in SAPHO syndrome: A systematic review.

No top-level findings curated for this source.

PMID:28532819

IL-23/Th17 targeted therapies in SAPHO syndrome. A case series.

No top-level findings curated for this source.

PMID:12184437

Pamidronate treatment in SAPHO syndrome.

No top-level findings curated for this source.

PMID:25602062

Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice.

No top-level findings curated for this source.

PMID:20032092

Genetic susceptibility factors in a cohort of 38 patients with SAPHO syndrome: a study of PSTPIP2, NOD2, and LPIN2 genes.

No top-level findings curated for this source.

PMID:28499891

SAPHO, autophagy, IL-1, FoxO1, and Propionibacterium (Cutibacterium) acnes.

No top-level findings curated for this source.

Ask OpenScientist

OpenScientist Report

Definitions

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Diagnosis

Prevalence

Epidemiology

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References